Tofacitinib citrate
A3921192Final Protocol Amendment 2, 04 Dec 2017
Page 1
A PHASE 3B/4 RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED 
STUDY OF METHOTREXATE (MTX) WITHDRAWAL IN SUBJECTS WITH 
RHEUMATOID ARTHRITIS (RA) TREATED WITH TOFACITINIB 11MG 
MODIFIED RELEASE (MR) FORMULATION 
Compound: CP 690,550
Compound Name: [CONTACT_167195] (US) Investigational New 
Drug (IND) Number:
European Clinical Trials Database 
(EudraCT) Number:2016-001825-15
Protocol Number: A3921192
Phase: Phase 3B/4CCI
Tofacitinib citrate
A3921192
Final Protocol Amendment 2, 04 Dec 2017
Page 2Document History
Document Version Date Summary of Changes 
Original protocol 09May 2016 Not applicable (N/A)
Amendment 1 09 Feb 2017 Belgiu m, Cz ech Republic, German y, Hungary , 
Italy, Poland, Spain, [LOCATION_008] country  
specific amendment.   The following changes were 
made:
1.Exclusion of subjects screened in 
Belgiu m, 
Czech Republic, [LOCATION_013] , Hungary , Italy, 
Poland, Spain, and the [LOCATION_008] who
have resided in or traveled in areas of endemic 
tuberculosis or endemic my coses.
2.Addition of Quantiferon testing at week 24 for 
all patients.
3.Addition of text to Section 1.2.1 that 
tofacitinib is under review in the EU and not 
yet approved.
4.Clarification to the Schedule of Activities and 
Section 7.2
that careful assessment of the skin 
for melanoma and nonmelanoma skin cancer 
is part of the Assessment of New Ph ysical 
Findings.
5.Addition of a statement regarding the risk of 
administration of NSAIDs and methot rexate 
and the prohibition of the use of folate 
antagonists during the study .
6.Clarification of discontinuation criteria.
7.Change to Section 7.16 and 7.17 indicating 
that CRP and ESR are blinded to the 
investigator and site staff after randomization 
instead of screening.
8. Changes to Section 4.4.5 Contraception and 
Reproductive Status section added in 
Appendix 7. 

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, 04 Dec 2017
Page 3Amendment 2 04Dec2017 The following change s were made :
1.Addition of text to Section 1.2.1 that 
tofacitinib has been approved in the EU. 
2.Addition of the ECG at End of Study  visit in 
the Schedule of Activities and in Section 
6.2.7.
3.
The number of subjects enrolled was 
increased from 580 to 680 .
4. T he LDA assessment was changed from 
DAS28-4(ESR) <3.2 and DAS28- 4(CRP) 
<3.2 to DAS28 -4(ESR)  3.2and 
DAS28
-4(CRP)  3.2.
5.
Stool examination for parasites in Peru (Table 
4; Clinical L aboratory  Tests) will be deleted 
since Peru is not involved this study .
6. C hange s from baseline intender/painful joint 
counts, swollen joint counts, subject 
assessment of arthritis pain, subject global 
assessment of arthritis, 
and physician global 
assessment of arthritis were added as other 
efficacy endpoints.
The following changes previously  described in 
the protocol administrative change letters (PACL) 
dated 17Jun2016, 14Jul2016, 05J ul2017 and 
07Sep2017 were made:
1.In Section 7.4 , Electrocardiogram , the 
electrocardiogram (ECG) at the End of Study  
visit was deleted and compari son of the End 
of Study  ECG was not to be completed per the 
PACL  dated 17Jun2016
.  However, the 
decision has bee n made to keep the ECG at 
the End of Study  visit so this change will not 
be made.
2.In Sections 6.1 (screening), 6.2.4 (Visit 3) and 
6.2.6 (Visit 5): the sentence “Subjects are 
required to fast for at least 6 hours prior to the 
visit”is deleted.
3.In Section 6.2.2 (Visit 1): 
“Smoking history  
and alcohol consumption ”will be added as 
one of the information collected.
4.In Sections 7.16, C -Reactive Protein (CRP)
and 7.17, Ery throcy te Sedimentation Rate 

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, 04 Dec 2017
Page 4(ESR) will be changed so that the Investigator 
and other site personnel participating in the 
study  and [COMPANY_007] study  personnel will be kept 
blinded of the results of this test after the 
randomization visit .
5. In Section 4.2, Exclusion Criteria, Criterion 
8b, has been 
revised to also exclude an y prior 
JAK inhibitor usage . 
6. Section 9.6 has been retitled and includes 
information regarding potential safet y and 
efficacy  anal yses of data obtained in the Open 
Label Phase of the stud y.
7. In Appendix 3, Prohibited Concomitant 
Medications: The medication "baricitinib 
(Olumiant)" has been added to the Prohibited 
Concomitant Medications table, listed under 
Nonbiologic DMARDs.
8.In Section 3.0, Study  Design:
a.“The enrollment will be monitored by  
[CONTACT_167160]  50% of 
enrolled subjects will have moderate 
disease activity  (defined as DAS28 (ESR) 
>3.2 and <5.1) and approximately  50% 
will have severe disease activity  (defined 
as DAS28 (ESR) >5.1).”is removed 
from the protocol.
b.“In addition, the proportion of subjects 
who have been exposed to one or more 
biologics prior to enro
llment ” is changed 
to “In addition, the proportion of subjects 
who have had an insufficient response to 
one or more biologics prior to enrollment ”
This amendment incorporates all revisions to date, including amendments made at the 
request of country  healt h authorities and institutional review boards (I RBs)/ethics committees 
(ECs).

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, [ADDRESS_194311] OF FIGURES .................................................................................................................10
APPENDI CES .........................................................................................................................10
PROTOCOL  SUMMARY .......................................................................................................11
STUDY DESIGN .....................................................................................................................15
SCHEDUL E OF ACTIVITI ES................................................................................................17
1. INTRODUCTION ...............................................................................................................20
1.1. Mechanism of Action/I ndication .............................................................................20
1.2. Background and Rationale
......................................................................................20
1.2.1. Tofacitinib I mmediate Release (IR) Formulation .......................................20
1.2.2. Tofacitinib Modified Release (MR) Formulation
.......................................21
1.2.3. Rationale .....................................................................................................22
1.2.4. Single Reference Safet y Documen t (SRSD) ..............................................22
2. STUDY OBJECTIVES AND ENDPOINTS .......................................................................22
2.1. Objectives ................................................................................................................22
2.1.1. Primary  Objectives .....................................................................................22
2.1.2. Secondary  Objectives .................................................................................22
2.1.3. Other Objectives .........................................................................................23
2.1.4. Exploratory  Objectives ...............................................................................23
2.2. Endpoints .................................................................................................................23
2.2.1. Efficacy  Endpoints ......................................................................................23
[IP_ADDRESS]. Primary  Efficacy Endpoint ........................................................23
[IP_ADDRESS]. Secondary  Efficacy  Endpoints ..................................................23
[IP_ADDRESS]. Other Efficacy  Endpoints ..........................................................24
[IP_ADDRESS]. Safet y Endpoints .......................................................................24
[IP_ADDRESS]. Exploratory  Endpoints ...............................................................[ADDRESS_194312] SEL ECTION ................................ ................................ ................................ ......26
4.1. I nclusion Criteria .....................................................................................................26
4.2. Exclusion Criteria
....................................................................................................29

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, 04 Dec 2017
Page 64.3. Randomization Criteria ...........................................................................................32
4.4. L ifesty le Guidelines ................................................................................................32
4.4.1. Non
-Pharmacologic Interventions ..............................................................32
4.4.2. Vaccine and Exposure to Infections Guidelines .........................................32
4.4.3. Dietary  Supplements ...................................................................................33
4.4.4. Surgery ........................................................................................................33
4.4.5. Contraception and Reproductive Status
......................................................34
4.5. Sponsor’s Qualified Medical Personnel ..................................................................[ADDRESS_194313] Supplies .............................................................................37
5.4.1. Dosage Form(s) and Packagin
g..................................................................[ADDRESS_194314] Supplies ........................................40
5.8. Concomitant Treatment(s) .......................................................................................40
5.8.1. Allowed Concomitant Medications ............................................................41
[IP_ADDRESS]. Treatment for Latent Tuberculosis ............................................41
[IP_ADDRESS]. Stable Background Arthritis Therap y
.......................................41
5.8.2. Disallowed Concomitant Medications ................................ ........................ 42
[IP_ADDRESS]. Disease Modify ing Antirheumatic Drugs (DMARDs) .............42
[IP_ADDRESS]. I mmune -Modulating Bi ologic Products
....................................42
[IP_ADDRESS]. CYP3A4 and CYP2C19 Inhibitors and CYP3A4 Inducers ......42
[IP_ADDRESS]. I mmunizations ...........................................................................43
[IP_ADDRESS]. I nvestigational medication ........................................................43
5.9. Rescue Medication ..................................................................................................43

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, 04 Dec 2017
Page 76. STUDY PROCEDURES .....................................................................................................43
6.1. Screening .................................................................................................................43
6.2. Study  Period ............................................................................................................45
6.2.1. Visit Windows ............................................................................................46
6.2.2. Visit 1 (Baseline Visit; Day  1)
....................................................................46
6.2.3. Visit 2 (Week 6; Day  42)............................................................................48
6.2.4. Visit 3 (Week 12; Day  84)
..........................................................................48
6.2.5. Visit 4 (Randomization; Week 24; Day  168) .............................................49
6.2.6. Visit 5 (Week 36; 
Day 252)........................................................................51
6.2.7. Visit 6 (End of Study  Visit; Week 48; Day  336/Early  Withdrawal 
Visit) ................................................................................................................51
6.2.8. Telephone Follow -up (At least 28days following last dose of study  
drugs) ...............................................................................................................[ADDRESS_194315] Radiograph ....................................................................................................54
7.4. Electrocardiogram ...................................................................................................54
7.5. Assessments of Disease Activity .............................................................................54
7.6. Joint Counts .............................................................................................................55
7.6.1. Tender/Painful Joint Count (28 Joint Count)
..............................................55
7.6.2. Swollen Joint Count (28 Joint Count) ........................................................[ADDRESS_194316] Global Assessment of Arthritis ..................................................................56
7.9. Phy sician Global Assessment of Arthritis
...............................................................56
7.10. Health Assessment Questionnaire –Disability  Index (HAQ -DI)
.........................56
7.11. SF -
36Health Survey (Version 2, Acute) ..............................................................56
7.12. EuroQol EQ -5D Health State Profile ....................................................................56
7.13. Work Productivity and Activity  Impairment (WPAI ) Questionnaire ...................57
7.14. Functional Assessment of Chronic Illness Therap y (FACIT) -Fatigue Scale ......57
7.15. Routine Assessment of Patient I ndex Data 3 (RAPI D3).......................................57

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, 04 Dec 2017
Page 87.16. C- reactive Protein (CRP) ......................................................................................57
7.17. Ery throcy te Sedimentatio n Rate (ESR)
.................................................................57
7.18. Clinical L aboratory Tests ......................................................................................57
7.19. Pregnancy  Testing .................................................................................................59
7.20. Adjudicated Events ...............................................................................................60
7.21. Banked Biospecimens ...........................................................................................60
7.21.1. Markers of Drug Response
.......................................................................60
7.21.2. Additional Research
..................................................................................61
7.22. Assessment of Suicidal I deation and Behavior (SI B)...........................................[ADDRESS_194317] Findings
..........................................................................................68
8.7. Serious Adverse Events ...........................................................................................68
8.7.1. Protocol
-Specified Serious Adverse Events ...............................................69
8.7.2. Potential Cases of Drug -
Induced Liver Injury............................................69
8.8. Hospi[INVESTIGATOR_059] ........................................................................................................70
8.9. Severity  Assessment ................................................................................................71
8.10. Causality  Assessment ............................................................................................71
8.11. Exposure During Pregnancy ..................................................................................72
8.12. Occupational Exposure .........................................................................................73
8.13. Wi thdrawal Due to Adverse Events (See Also the Section on Subject 
Withdrawal)
...............................................................................................................73
8.14. Eliciting Adverse Event I nformation ....................................................................73
8.15. Reporting Requirements ................................ ................................ ........................ 73
8.15.1. Serious Adverse Event Reporting Requirements .....................................74

Tofacitinib citrate
A3921192Final Protocol Amendment 2, 04 Dec 2017
Page 98.15.2. Non-serious Adverse Event Reporting Requirements..............................74
8.15.3. Sponsor’s Reporting Requirements to Regulatory Authorities ................74
9. DATA ANALYSIS/STATISTICAL METHODS...............................................................74
9.1. Sample Size Determination.....................................................................................759.2. Descriptive Analysis ...............................................................................................759.3. Efficacy Analysis ....................................................................................................75
9.3.1. Analysis of the Primary Endpoint...............................................................759.3.2. Analysis of Sec ondary Endpoints...............................................................76
9.4. Analysis of Other Efficacy and Exploratory  Endpoints..........................................76
9.5. Safety Analysis........................................................................................................76
76
9.7. Data Monitoring Committee ...................................................................................779.8. Safety Event Adjudication/Review Committees.....................................................[ADDRESS_194318] KEEPI[INVESTIGATOR_1645] .............................................................78
11.1. Case Report Forms/Electronic Data Record .........................................................7811.2. Record Retention...................................................................................................[ADDRESS_194319]/Ethics Committee......................................................7912.2. Ethical Conduct of the Study ................................................................................7912.3. Subject Information and Consent..........................................................................8012.4. Subject Recruitment ..............................................................................................8012.5. Reporting of Safety Issues and Serious Breaches of the Protocol or ICH 
GCP ...........................................................................................................................[ADDRESS_194320] OF TABLES
Table 1. Treatment arms .....................................................................................................36
Table 2. DMARDs –
Required Washout Period.................................................................[ADDRESS_194321] OF FIGURES
Figure 1. Study  Design .........................................................................................................26
APPENDICES
Appendix 1. Abbreviations ......................................................................................................86
Appendix 2. The 2010 American College of Rheumatology /Europe an League Against 
Rheumatism Classification Criteria for Rheumatoid Arthritis
.............................89
Appendix 3. Prohibited Concomitant Medications
..................................................................91
Appendix 4. Cockcroft
-Gault Formula for Estimating GFR ...................................................92
Appendix 5. Approximate Equivalent Morphine Doses Of Opi[INVESTIGATOR_36570]
......................93
Appendix 6. Rescue Therapy ...................................................................................................94
Appendix 7. Belgium, Czech Republic, German y, Hungary , Italy, Poland, Spain, and 
[LOCATION_008] Specific Protocol Requirements ...............................................96

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, 04 Dec 2017
Page 11PROTOCOL SUMMARY
Background and Rationale
Tofacitinib (CP- 690,550) is a potent, selective inhibitor of the Janus kinase (JAK) family of 
kinases with a high degree of selectivity  against other kinases in the human genome .1In 
kinase assay s, tofacitinib, inhibits JAK1, JAK2, JAK3, and to a lesser extent ty rosine kinase 
2(TyK2). In cellular settings where JAK kinases signal in pairs, tofacitinib preferentiall y 
inhibits signaling by [CONTACT_167161]3 and/or JAK1 with 
functional selectivity  over receptors that signal via pairs of JAK2 .2Inhibition of JAK1 and 
JAK3 by [CONTACT_167162], including interleukin (IL) - 2, - 4, -7, -9, -15, and - 21. These cy tokines 
are integral to ly mphocy te activation, development, homeostasis, proliferation, and function; 
therefore, inhibition of their signaling may  result in modulation of multiple aspects of the 
immune response. In addition, inhibition of JAK1 will result in attenuation of signaling by  
[CONTACT_167163] -inflammatory  cytokines, such as IL -6and interferon (I FN)γ .3,4At higher 
exposures, inhibition of ery thropoietin, prolactin, and other hormones can occur via 
inhibition of JAK2 signaling. 
The Phase [ADDRESS_194322] demonstrated that tofacitinib 
Immediate Release ( IR) 5mg twice daily  (BID) consistently  reduces signs and sy mptoms of 
rheumatoid arthritis ( RA), improves phy sical function and other subject- reported outcomes 
such as fatigue , pain and health -related aspects of quality  of life in subjects with moderate to 
severe RA. Combined with its inhibition of the progression of structural damage, the 
development program has demonstrated tofacitinib as an effective targeted sy nthetic 
disease-modify ing antirheumatic drug ( DMARD ) in treating RA.5-10Ongoing long- term 
extension and Phase 3b/[ADDRESS_194323] authorization safety studies are aimed to demonstrate 
sustained efficacy and a consistent safet y profile as seen in the Phase 2 and 3 controlled 
clinical trials. Data from completed and ongoing clinical trials demonstrate tofacitinib’s 
manageable safety  profile. Theoverall benefit -risk profile of 
the tofacitinib I R formulat ion 
remains favorable (refers to Investigator Brochure ( IB) for further details). Tofacitinib I R 
5mg BI D is currentl y approved in the [LOCATION_002] (US) , European Union ( EU) ,and 
40other countries for the treatment of adult patients with RA .
To enable once dail y (QD) dosing, [COMPANY_007] has developed a modified release (MR) osmotic 
tablet formulation of tofacitinib at a dose strength of [ADDRESS_194324] been completed to characterize the biopharmaceutical aspects of the tofacitinib 
MR 11mg QD formulation and establish similarity  in key  pharmacokinetic (PK) exposure 
parameters and relative bioavailability (BA) as compared to the currentl y approved 
tofacitinib I R 5mg BID formulation.  The tofacitinib MR clinical pharmacology  
development program has demonstrated that the MR 11 mg QD dose has equivalent Area 
Under Concentration (AUC) and C maxcompared to the currently  approved IR 5
mg BID 
dose.   Exposure -response (E -R) relationships from the I R development program show that 
Cavis the relevant parameter for efficacy and that the slightly  lower (29%) C minof the MR 
formulation is not clinically  important to the efficacy  of tofacitinib.   These data support the 
consistent efficacy  between MR 11 mg QD and IR 5 mg BI D.  Likewise, the overall

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, 04 Dec 2017
Page 12similarity  in PK parameters and duration of JAK1/3 inhibition over the dosing interval, along 
with exposure -safet y relationships from the I R program, indicate that the safety  of MR 11 mg 
QD will be consistent with that of the I R 5mg BID.  The MR f ormulation of tofacitinib was 
also shown to be generally safe and well tolerated in 7healthy  volunteer studies . 
Collectively , these data support a favorable benefit -risk profile for the MR 11 mg QD 
formulation for the treatment of adult patients with mod erately to severel y active RA, and the 
efficacy  and safet y of tofacitinib MR 11 mg QD are expected to be consistent with that 
demonstrated for tofacitinib I R 5mg BID. A New Drug Application (NDA) for the MR 
osmotic tablet formulation of tofacitinib (dose d at 11 mgQD) for the treatment of RA is 
under review b y the Food and Drug Administration ( FDA ).
The tofacitinib IR 5mg BID formulation has demonstrated efficacy  both as a monotherap y 
and in 
combination with methotrexate (MTX) in previous trials. Howeve r, it remains 
unknown whether the tofacitinib efficacy  will be sustained after the withdrawal of MTX 
among RA patients who achieve low disease activity following treatment with tofacitinib
plus MTX . Results of the current study  will inform the value of the continued MTX 
treatment among subjects who have responded to combined therapy  of tofacitinib and MTX. 
A MR 11mg QD regimen has the potential to offer an additional dosing option to subjects, 
and based on the equivalence of key  pharmacokinetic parameters , efficacy  and safet y are 
expected to be consistent with that demonstrated for tofacitinib I R 5mg BID. Therefore, the 
current study will evaluate the sustained efficacy  and safety of the tofacitinib MR 11 mg QD 
regimen among RA patients undergoing blinde d withdrawal of MTX. 
Complete information for tofacitinib may  be found in thesingle reference safet y document 
(SRSD), which for t his study  isthe tofacitinib I B .  The SRSD for MTX is the Summary  of 
Product Characteristics (SPC). 
STUDY OBJECTIVES AND END POINTS
OBJECTIVES
Primary Objectives
To compare the efficacy  of tofacitinib MR 11mg monotherapy  to tofacitinib MR 11mg with
continued MTX, as measured b y the change in the Disease Activity Score utilizing 
4components including ery throcy te sedimentation ra te (DAS28-4 (ESR)) from 
randomization (at W eek 24) to the end of the double -blind MTX withdrawal phase (at 
Week48).
Secondary Objectives
To compare the efficacy  oftofacitinib MR 11mg monotherapy  to tofacitinib MR 
11mg with continued MTX inthe double- blind MTX withdrawal phase (at Week 36) , 
as measured b yDAS 28-4 (ESR).

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, 04 Dec 2017
Page 13To compare the efficacy  oftofacitinib MR 11mg monotherapy  to tofacitinib MR 
11mg with continued MTX inthe double- blind MTX withdrawal phase (at W eeks
48and 36) , as measured by [CONTACT_83927] A ctivity  Score 28-4 (C-reactive protein)
(DAS28 -
4(CRP)), Clinica l Disease Activity  Index (CDAI), Simplified Disease 
Activity  Index (SDAI), Low Disease Activity  (LDA) ,remission, ACR20, ACR 50, 
and ACR 70.
To compare effects of tofacitinib MR 11mg monother apy to tofacitinib MR 11mg 
with continued MTX on health outcome measures inthedouble -blind MTX 
withdrawal phase 
(at W eeks 48 and 36), as measured by  [CONTACT_167164] -Disability  Index (HAQ -DI), Medical Outcomes Survey  
Short Form 
-36(SF-36), Work Productivity  and Activity  Impairment (WPAI), 
European Quality  of Life - 5 dimensions questionnaire (EuroQol EQ- 5D), and 
Functional Assessment of Chronic Illness Therapy  (FACIT) -Fatigue scale .
To evaluate the safet y and tolerability  of tof acitin ib MR 11mg monotherapy  versus
tofacitinib MR 11mg with continued MTX.
Other Objectives
To describe efficacy  of treatment with tofacitinib 11mg with MTX inthe open- label 
run-in phase (at Weeks 12 and 24) , as measured by  [CONTACT_50999]2 8-4 (ESR), 
DAS 28-4 (CRP), CDAI , SDAI , LDA, remission, ACR20, ACR 50, ACR70 .
To describe effects of treatment with tofacitinib MR 11mg with MTX on health 
outcome measures in the open- label run -in phase (at W eeks 12 and 24) , asmeasured 
by [CONTACT_53820] -DI, SF-36, WPAI, EuroQol EQ -5D, and FACI T-Fatigue scale .
Exploratory Objectives
To collect exploratory  biomarker/genomics samples for bio -banking. 
US and Canada ONLY: To explore effects of treatment with tofacitinib MR 11mg 
with/without MTX on health outcome measure in the open -label run -in pha se (at 
Weeks 12 and 24) and the double-blind MTX withdrawal phase (at Weeks 48 and 
36), as measured b y Routine Assessment of Patient I ndex Data 3 (RAPID3) .
Endpoints 
Efficacy Endpoints
Primary Efficacy Endpoint
Change in DAS28 -4(ESR) score from randomiza tion (at W eek 24) to the end of 
double -blind MTX withdrawal phase (at Week 48). 

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, 04 Dec 2017
Page 14Secondary Efficacy Endpoints
Change in the DAS28-4 (ESR) from W eek 24 to Week 36;
Changes in the DAS28 -4(CRP), CDAI  and SDAI, respectivel y, from Week 24 to 
Week 48 and from W eek 24 to Week 36; 
LDA as assessed b y DAS28 -4(ESR ) 3.2, DAS28- 4(CRP) 3.2, CD AI10and 
SDAI11, respectively , at Weeks 48 and 36;
Remission as assessed by [CONTACT_104706] -EULAR Boolean remission 
criteria ,11DAS28-4 (ESR) <2.6, DAS28 -4(CRP)<2.6, CDAI ≤2.8 and SDAI ≤3.3, 
respectivel y, at Weeks 48 and 36;
ACR20, ACR 50, and ACR70 responses, respectively, at Weeks 48 and 36;
Change in the HAQ -DI, the SF -36(8domain scores and 2 component scores), WPAI , 
EuroQol EQ -5D and the FACI T-Fatigue sc ale score, respectivel y, from Week 24 to 
Week 48 and from week 24 to Week 36;
HAQ- DI respon se (ie, decrease of at least 0.22) at Weeks 48 and 36.
Other Efficacy Endpoints
Changes in DAS28-4 ( ESR), DAS28-4 (CRP), CDAI, SDAI, HAQ -DI, 
SF-36 (8domain scores a nd 2 component scores), WPAI , EuroQol EQ -5D score and 
FACI T-Fatigue scale score, respectivel y, from day 1 to Week 12 and from day  1to 
Week 24;
LDA as assessed b y DAS28 -4(ESR) <3.2, DAS28 -4(CRP) < 3.2, CDAI 10and 
SDAI11, respectively , at Weeks 12 and 24;
Remission as assessed by [CONTACT_104706] -EULAR Boolean remission criteria, 
DAS28-4 (ESR)< 2.6, DAS28-4 (CRP)<2.6, CDAI 2.8and SDAI3.3, respectively , 
at W eeks 12 and 24;
ACR20, ACR 50, and ACR70 responses, respectively, at Weeks 12 and 24;
HAQ- DI response (ie, decreas e of at least 0.22) at Weeks 12 and 24.
Changes in tender/painful joint counts, swollen joint counts , subject assessment of 
arthritis pain, subject global assessment of arthritis, phy sician global assessment of 
arthritis, and CRP, respectively , from day  1to Week 12 and from day  1to Week 24 , 
from Week 24 to Week 48 and from week 24 to Week 36 .

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, 04 Dec 2017
Page 15Safety Endpoints
All adverse events (AEs), including serious adverse events (SAEs) .
Clinically  significant abnormal laboratory  parameters.
Exploratory Endpoints
Exploratory biomarker/genomics endpoints will be specified in a separate protocol 
and/or statistical anal ysis plan if exploratory anal yses utilizing the bio -banked 
exploratory  genomic and biomarker samples across tofacitinib studies or across 
multiple program s are conducted.
US and Canada ONLY : RAPI D3summary  score at Weeks 12, 24, 36 and 48.
STUDY DESIGN
Study  A3921192 is a 12- month randomized, double -blind, placebo -controlled withdrawal 
study  in a total of approximately  580 subjects with moderate to severe RA(defined as CDAI
>10and DAS28 (ESR)3.2)who are insufficiently  respond ingto the irstable dose of MTX
treatment .  The enrollment will be monitored by [CONTACT_167165]  50% of 
enrolled subjects will have moderate disease activity
 (defined as DAS28 (ESR)  3.2and 
5.1) and 
approximatel y 50% will have severe disease a ctivity  (defined as DAS28 (ESR) 
>5.1).  In addition, the proportion of subjects who have had an insufficient response to one 
or more biologics prior to the enrollment should be25% (ie, 145subjects).
After reviewing the rate of achievement of LDA and monitoring the discontinuation rate in 
the op
en-label period, the decision was made to increase in enrollment numbers from 
approximatel y 580to 680 factoring in a discontinu ation rate of approximately  15% during 
the open label run -in phase .  As of 02 Aug 2017, study  was 50% enrolled with 81% having 
severe disease activity .  The LDA rate (~79% based upon a small sample size) was higher 
than protocol assumptions and historic da ta.  It is expected that e nrolling >50% of subjects 
with severe disease activity  will result in a sufficient n umber of subjects with L DA at 
Week 24.  Therefore , the enrollment requirement of 50% of subjects with severe disease 
activity  and 50% with moderat e disease activity was removed from the protocol
.
Following enrollment, all subjects will receive open-label tofacitinib MR 11mg QD added to
MTX at their previousl y stabilized dose for 24 weeks (run- in phase).  At the end of the run -in 
phase ( Week 24), onl y subjects who achieve low disease activi ty (LDA) as assessed b y 
CDAI  (ie, CDAI ≤10) (approximately  232 subjects) will be randomized in tothe 24-week 
double -blind, placebo -controlled MTX withdrawal phase.  Subjects who do not achieve LDA 
(defined b y CDA I
>10) at this time point will be discontinued from the study .  Subjects 
entering 
the double- blind phase will be randomized in a 1:1 ratio to either continue the run -in 
phase treatment regimen (tofacitinib MR 11mg QD with blinded MTX) or to receive 
tofacitinib monotherap y (tofacitinib 
MR 11mg QD with blinded matching placebo for MTX).  
Randomization will be stratified by[CONTACT_1130]’ s prior exposure 
to a biologic DMARD .  
Randomized subjects will be followed up to the end of Week 48.  The primary ef ficacy  

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, 04 Dec 2017
Page 16endpoint is the change in DAS28-4 (ESR) from randomization (at Week 24) to the end of 
double -blind MTX withdrawal phase (at Week 48) .
STATISTICAL METHODS
Based on estimated CDAI -defined 
low disease activity rate of 40% derived from prior P hase 
3studies and factoring in a discontinuation rate of approximatel y 15% during the open label 
run-in phase , approximately [ADDRESS_194325] 232subjects being randomize d into the blinded MTX withdrawal phase at W eek 24.   
With a two -sided Ty pe-I error of 5% and an assumed standard deviation (SD) of 1.4for the 
difference in change from randomization in DAS28-4 (ESR) between the two arms, a sample 
size of 232 subjects randomized at Week 24 would provide 90% power to declare 
non-inferiorit y of tofacitinib monotherapy relative to tofacitinib plus methot rexate with a 
non-inferiorit y margin of 0.6.
The primary  endpoint of change from randomization in DAS28 -
4(ESR) at Week [ADDRESS_194326] model of repeated measures 
(MMRM) that includes the fixed effec ts of treatment, visit, treatment- by-visit interaction, 
prior use of a biological DMARD, and baseline DAS28 -4 (ESR) value as a covariate.   
Within -subject variability will be accounted for using a random effect with an unstructured 
covariance matrix.   Chang e from randomization at any  visit post -randomization will be 
defined as the DAS28 -
4(ESR) value at that visit minus the value at randomization.
The anal ysis will be based on the Full Analy sis Set (FAS), which is defined as those subjects 
who received at le ast one dose of tofacitinib MR 11mg plus MTX during the open label
run-inperiod, and were randomized and received at least one dose of the randomized 
investigational drug regimen (tofacitinib MR 11mg with MTX or tofacitinib MR 11mg with 
placebo for MTX) during the blinded MTX withdrawal period .
A robustness anal ysis based on a per-protocol analy sis set will be performed.   Sensitivity
analyses using different methods of handling missing data will also 
be conducted ; further 
details will be outlined in the SA P.
STATISTICAL DECISION RULES
The primary  anal ysis will be a non- inferiority  test to show that tofacitinib MR 11mg 
monotherap y is not less effective (non -inferior) than tofacitinib MR 11mg with continued 
MTX within the margin of non -inferiority  set at 0.6 (ie, the difference in mean change from 
randomization in DAS 28 -4(ESR) between the two arms ).  In other words, the change from 
randomization in DAS28 -4(ESR) for the tofacitinib MR 11mg with placebo for 
MTX arm 
may be less favorable than that for the tofac itinib MR 11mg with continued MTX arm b y no
more than 0.6.

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, 04 Dec 2017
Page 17SCHEDULE OF ACTIVITI ES
The schedule of activities table provides an overview of the protocol visits and procedures.  Refer to the STUDY PROCEDURES and 
ASSESSMENTS sections of the protocol for detailed information on each procedure and assessment required for compliance with the 
protocol .
The investigator may  schedule visits (unplanned visits ) inaddition to those listed on the schedule of activiti es(SOA) , in order to 
conduct evaluations or assessments required to protect the well -being of the subject.
Protocol Activities Screening 
VisitVisit 
1(Baseline)Visit 2 Visit 3 Visit 
4(Randomization)Visit 5 Visit 6 (End of 
Study/Early 
Withdrawal)kTelephone 
Follow -upo
Day -30
(+10 days; 
ie, -
40days)Day 1 Week 6
(Day 42)
(±5days)Week 12
(Day 84)
(±10 days)Week 24
(Day 168)
(±10 days)Week 36
(Day 252)
(±10 days)Week 48
(Day 
336)(±10 days)/early 
withdraw alAt least [ADDRESS_194327] 
dose of study 
drugs (+14 days)
Informed Consent X
Medical History, Prior 
Medication X
RA diagnosis X
Complete Physical Examination X XnX
Assessment of New Physical 
FindingsqX X X X
Inclusion/Exclusion criteria X X
Laboratory Testing
   Blood Chemistry X X X X X X X
   CRPaX X X X X X
   ESR X X X X X X
   Hematology X X X X X X X
   Banked biospecimens X X X X
   HIV Serology X
   HBsAg, HBcAb, HBsAbbX
  HCV Ab, HCV RNAbX
   Lipid Profile (fasting) X X X X
   Pregnancy test,c
   Contraceptive Check and
   DocumentationX X X X X X X
   QuantiFERON -Gold®™ X Xl
   Rheumatoid Factor X

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, 04 Dec 2017
Page 18Protocol Activities Screening 
VisitVisit 
1(Baseline)Visit 2 Visit 3 Visit 
4(Randomization)Visit 5 Visit 6 (End of 
Study/Early 
Withdrawal)kTelephone 
Follow -upo
Day -30
(+10 days; 
ie, -
40days)Day 1 Week 6
(Day 42)
(±5days)Week 12
(Day 84)
(±10 days)Week 24
(Day 168)
(±10 days)Week 36
(Day 252)
(±10 days)Week 48
(Day 
336)(±10 days)/early 
withdraw alAt least [ADDRESS_194328] 
dose of study 
drugs (+14 days)
   Anti-cyclic citrullinated 
   peptide (Anti-CCP) antibodyX
   FSH (if applicable)d  X
Urinalysis X
Chest X -ray or CTeX
ECG X X
Randomization X
Investigational Product 
DispensingX X X X
Joint Count (28)fX X X X X X
Subje ct Assessment of Arthritis 
PainX X X X X
Subject Global Assessment of 
ArthritisX X X X X
Physician Global Assessment of 
ArthritisX X X X X
HAQ-DIgX X X X X
SF-36 (Version 2, Acute) X X X X X
EuroQol EQ -5DhX X X X X
Work Productivity and Activity 
Impairment (WPAI) X X X X X
FACIT -FatigueiX X X X X
Routine Assessment of Patient 
Index Data 3 (RAPID3) (US 
and Canada O NLY )X X X X X
Safety Assessment/AE 
Reporting/Assessment for AEs 
Requiring AdjudicationjXmX X X X X X Xp
Concomitant Medication 
ReviewX X X X X X
Provide/review dosing diary X X X X X X
Return unused investigational 
products X X X X

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, 04 Dec 2017
Page 19a.After screening , the investigator and other site personnel participating in the study and Pfiz er study personnel will be kept blinded of the results of CRP.
b.See Exclusion Criteria 3 and Table 4 in Sectio n 7.17 for details.
c.Pregnancy tests (serum/urine) may also be repeated more frequently as per request of IRB s/ECs or if required by [CONTACT_427]. 
d.To confirm post -menopausal status , if applicable.
e.Chest ra diograph or Chest CT scan unless previously performed and documented within 3 months prior to screening.
f.Joint counts done by a blinded joint assessor. 
g.Health Assessment Questionnaire –Disability Index.
h.European Quality of Life 5 Dimension Questionnaire.
i.Functional assess ment of chronic illness therapy -fatigue scale .
j.Specific safety events will be submitted to the appropriate Safety Event Adjudication/Review  Committee for adjudication. 
k.Subjects who do not achieve LDA at Week 24 and are therefore not rand omized do not require a separate EOS visit except for QuantiFERON Gold®TM
In-Tube Test. 
l.QuantiFERON Gold®TMin-Tube Test will b e performed for ALL subjects (those who meet LDA and those who do not meet LDA at week 24) in Belgium, 
Czech Republic, [LOCATION_013], Hungary, Italy, Poland, Spain, and the [LOCATION_008] .  For all other countries the test will ONLY be performed for subjects 
who do not achieve LDA at Week 24 and are therefore no t randomized.
m.Report and assess AEs within appropriate reporting period. SeeSection 6.1for details.
n.Height will not be collected in the Case Report Form (CRF).
o.Can be combined w ith the End of Study visit as long as the Telephone Follow -upoccurs at least [ADDRESS_194329] administration of study drugs.
p.Includes a query of pregnancy status in addition to AEs. 
q.Assessment of new physical findings consists of an abbreviated physical examination assessing the following:  weight, vital s igns, skin examin ation 
including a careful examination f or melanoma and nonm elanom a skin cancer, lungs, heart, lower extremities for peripheral edema, abdomen, and lymph 
nodes.

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, 04 Dec 2017
Page 201.INTRODUCTION
1.1.Mechanism of Action /Indication
Tofacitinib (CP- 690,550) is a potent, selective inh ibitor of the Janus kinase (JAK) family  of 
kinases with a high degree of selectivity  against other kinases in the human genome .1In 
kinase assay s, tofacitinib, inhibits JAK1, JAK2, JAK3, and to a lesser extent tyrosine kinase 
2(TyK2). In cellular settings where JAK kinases signal in pairs, tofacitinib preferentiall y 
inhibits signaling by [CONTACT_167161]3 and/or JAK1 with 
functional selectivity  over receptors that signal via pairs of JAK2 .2Inhibition of JAK1 and 
JAK3 by [CONTACT_167162], including interleukin (IL) -2, -
4, -7, -9, - 15, and - 21. These cy tokines 
are integral to ly mphocy te activation, development, homeostasis, proliferation, and function; 
therefore, inhibition of their signaling may  result in modulation of multiple aspects of the 
immune response. In addition, inhibition of JAK1 will result in attenuation of signaling by  
[CONTACT_167163] -inflammatory  cytokines, such as IL -6and interferon (I FN).3,4At higher 
exposures, inhibition of ery thropoietin, prolactin, and other hormones can occur via 
inhibition of JAK2 signaling.
1.2.Background and Rationale
1.2.1. Tofacitinib Immediate Release (IR) Formulation
The Phase 2 and 3 studies in RA development program demonstrated that tofacitinib I R 5mg 
twice dail y (BID)consistently  reduces si gns and sy mptoms of RA, improves phy sical 
function and other subject -reported outcomes such as fatigue, pain and health -related aspects 
of quality  of life in subjects with moderate to severe RA. Combined with its inhibition of the 
progression of structura l damage, the development program has demonstrated tofacitinib as 
an effective targeted s ynthetic DMARD in treating RA .5-10Ongoing long- term extension and 
Phase 3b/[ADDRESS_194330] authoriza tion safet y studies are aimed to demonstrate sustained efficacy and 
a consistent safet y profile as seen in the Phase 2 and 3 controlled clinical trials. 
Data from completed and ongoing clinical studies demonstrate tofacitinib’s manageable 
safet y profile. As of April 2014, O ver 10,[ADDRESS_194331] 1 study  dose of 
oraltofacitinib in either a randomized clinical study or a long -term extension (L TE) study  in 
multiple indications
. Approximat ely [ADDRESS_194332] years of exposure in Phase 2, 3, 
3B/[ADDRESS_194333] been 
observed with the oral use of tofacitinib in the Phase
2and Phase 3studies include se rious 
and other important infections, including tuberculosis (TB) and herpes zoster; the potential 
for malignancies including ly mphoma; and the potential for gastr ointestinal (GI) 
perforations. Subjects receiving tofacitinib may  also be at increased risk of nonmelanoma 
skin cancers (NMSC).  Cardiovascular disease and interstitial lung disease (ILD) are findings 
seen in RA subjects receiving tofacitinib, and are recognized comorbidities for RA as well as 
being associated with other RA therapi[INVESTIGATOR_014].  Changes in laboratory  values have also been 
observed including a dose- dependent increase in low density  lipoprotein ( LDL) cholesterol 
and dose -dependent decreases in neutrophils and hemoglobin.  Other laboratory  changes 

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, 04 Dec 2017
Page 21observed with tofacitinib treatment include decreases in ly mphocy tes and increases in 
transaminases, serum creatinine, and creatine kinase (CK).  Laboratory  changes observed 
with tofac itinib treatment are manageable; recovery  of laboratory  changes upon 
discontinuation of tofacitinib treatment is chara cteristically  observed.  Based on nonclinical 
data, there is the potential for tofacitinib to have effects on pregnancy  and the fetus.  More 
details of identified risks with tofacitinib in RA are presented in the XEL JANZ(tofacitinib 
citrate) Investigator Brochure (IB).
Based on 
the most recent data from clinical trials and post- marketing experience, the overall 
benefit -risk profile of the tofacitinib IR formulation remains favorable (refer to tofacitinib IB 
for further details) . Tofacitinib IR 5 mg BID i s currentl y approve d in the [LOCATION_002] (US) , 
European Union (EU), and40other 
countries .
1.2.2. Tofacitinib Modified Release (MR) Formulation
To enable once daily (QD) dosing, [COMPANY_007] has developed a modified release (MR) osmotic 
tablet formulation of tofacitinib at a dose strength of [ADDRESS_194334] been completed to characterize the biopharmaceutical aspects of the tofacitinib 
MR 11mg QD formulation and establish similarity  in key  pharmacokinetic (PK) exposure 
parameters and relative bioavailability (BA) as compared to the currentl y approved 
tofaci tinib I R 5mg BID formulation. The clinical pharmacolog y development program has 
demonstrated that the MR 11 mg QD
dose has equivalent Area Under Concentration (AUC)
and C maxcompared to the currentl y approved IR 5 mg BI D.Exposure -response (E -R) 
relationships from the IR development program show that C av is the relevant parameter for 
efficacy  and that the slightly  lower (29%) C min of the MR formulation is not clinically  
importa nt to the efficacy  of tofacitinib.   These data support the consistent efficacy between
MR11mg QD and IR 5mg BI D
.
Likewise, the overall similarity  in PK parameters and duration of JAK1/3 inhibition over the 
dosing interval, along with exposure -safet y relationships from the I Rprogram, indicate that 
the safet y of MR 11 mg QD will be consistent with that of the I R 5mgBID. Of the 172 total 
subjects in the 7 health y volunteer studies, 67 reported adverse events (AEs).  AEs were 
generall y similar between t he MR formulations and the I R tablets.  There were no deaths, 
serious adverse events (SAEs), severe AEs, or dose reductions/temporary  discontinuations 
due to AEs.  The majority  of AEs were considered to be mild and related to treatment , and 
none of the rep orted AEs were considered clinically  important. 
Collectively , these data support a favorable benefit -risk profile for the MR 11 mgQD 
formulation for the treatment of adult patients with moderatel y to severel y active RA, and
showed the efficacy  and safet yof tofacitinib MR 11 mg QD are expected to be consistent 
with that demonstrated for tofacitinib I R 5mg BID. A New Drug Application (NDA) for the
MR osmotic tablet formulation of tofacitinib (dosed at 11 mgQD) for the treatment of RA is 
under review b y the Food and Drug Administration (FDA).

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, 04 Dec 2017
Page 221.2.3. Rationale
The tofacitinib IR 5mg BID formulation has demonstrated efficacy  both as a monotherap y 
and in combination with methotrexate (MTX) in previous trials. However, it remains 
unknown whether the tofacitinib ef ficacy  will be sustained after the withdrawal of MTX 
among RA patients who achieve low disease activity
 following treatment with MTX plus 
tofacitinib. Results of the current study  willinform the value of the continued MTX 
treatment among subjects who hav e responded to combined therapy  of tofacitinib and MTX. 
A MR 11mg QD regimen has the potential to offer an additional dosing option to subjects, 
and based on the equivalence of key  pharmacokinetic parameters, efficacy  and safet y are 
expected to be consistent with that demonstrated for tofacitinib I R 5mg BID. Therefore, the 
current study will evaluate the sustained efficacy  and safety of the tofacitinib MR 11 mg QD 
regimen among RA patients undergoing blinded withdrawal of MTX. 
1.2.4. Single Reference Safety Do cument (SRSD)
Complete information for tofacitinib may be found in the single reference safet y document 
(SRSD), which for this study  is the tofacitinib I B. The SRSD for MTX is the Summary  of 
Product Characteristics (SPC). 
2. STUDY OBJECTIVES AND ENDPOINTS
2.1. O bjectives
2.1.1. Primary Objectives
Tocompare the efficacy  of tofacitinib MR 11mg monotherap y to tofacitinib MR 11mg with 
continued MTX, as measured b y the change in the Disease Activity Score utilizing 
4components including ery throcy te sedimentation rate (DAS28-4 (ESR)) from 
randomization (at W eek 24) to the end of the double -blind MTX withdrawal phase (at 
Week48).
2.1.2. Secondary Objectives
To compare the efficacy  of tofacitinib MR 11mg monotherapy  to tofacitinib MR 
11mg with continued MTX in the double- blind MTX w ithdrawal phase (at Week 36), 
as measur ed by [CONTACT_50999] 28-4 (ESR).
To compare the efficacy  of tofacitinib MR 11mg monotherapy  to tofacitinib MR 
11mg with continued MTX in the double
-blind MTX withdrawal phase (at W eeks 
48and 36), as measur ed by  [CONTACT_167166] 28-4 (C reactive protein) 
(DAS28 -
4(CRP)), Clinical Disease Activity  Index (CDAI), Simplified Disease 
Activity  Index (SDAI), Low Disease Activity  (LDA), remission, ACR20, ACR 50, 
and ACR 70. 

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, 04 Dec 2017
Page 23To compare effects of tofacitinib MR 11mg monotherap y to t ofacitinib MR 11mg 
with continued MTX on health outcome measures in the double- blind MTX 
withdrawal phase (at Weeks 48 and 36), as measured b y Health Assessment 
Disability  Questionnaire -Disability  Index (HAQ DI), Medical Outcomes Survey  
Short Form -36 (SF-36), Work Productivity  and Activity  Impairment (WPAI), 
European Quality  of Life 5 dimensions questionnaire (EuroQol EQ 5D), and 
Functional Assessment of Chronic Illness Therapy  (FACIT) -Fatigue scale.
To evaluate the safet y and tolerability  of tofacitinib MR 11mg monotherapy versus 
tofacitinib MR 11mg with continued MTX.
2.1.3. Other Objectives
To describe efficacy of treatment with tofacitinib 11mg with MTX in the open -label 
run-in phase (at Weeks 12 and 24) , as measured by  [CONTACT_50999]28 -4 (ESR), 
DAS 28-4 (CRP), CDAI ,SDAI , LDA, remission, ACR20, ACR 50 and ACR70.
To describe effects of treatment with tofacitinib MR 11mg with MTX on health 
outcome measures in the 
open -label run -in phase (at Weeks 12 and 24) , as measured 
by [CONTACT_53820] -DI, SF-36, WPAI, EuroQol EQ -5D, and FACI T-Fatig ue scale .
2.1.4. Exploratory Objectives
To collect exploratory  biomarker/genomics samples for bio- banking.
US and Canada ONLY : To explore effects of treatment with tofacitinib MR 11mg 
with/without MTX on health outcome measure in the open -label run -in phase (at 
Weeks 12 and 24) and the double- blind MTX withdrawal phase (at Weeks 48 and 
36), as measured b y Routine Assessment of Patient I ndex Data 3 (RAPID3) .
2.2.Endpoints
2.2.1. Efficacy Endpoints
[IP_ADDRESS]. Primary Efficacy Endpoint
Change in DAS28 -4 (ESR) score from randomization (at Week 24) to the end of 
double -blind MTX withdrawal phase (at Week 48 )
.
[IP_ADDRESS]. Secondary Efficacy Endpoints
Change in the DAS 28-4(ESR) from Week 24 to Week 36;
Changes in the DAS28 -4(CRP), CDAI  and SDAI, respectivel y,from Week 24 to 
Week 48 andfrom Week 24 toWeek 36 ;
LDA as assessed b y DAS28 -4(ESR)  3.2, DAS28- 4(CRP) 3.2, CDAI10and 
SDAI11, respectively , at Weeks 48 and 36;

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, 04 Dec 2017
Page 24Remission as assessed by [CONTACT_104706] -EULAR Boolean remission 
criteria ,11DAS 28-4 (ESR) < 2.6, DAS 28-4(CRP) <2.6, CDAI 2.8and SDAI3.3, 
respectivel y, at 
Weeks 48 and 36;
ACR20, ACR 50, and ACR70 response s, respectively ,at W eeks 48 and 36 ;
Change in the HAQ -DI, the SF -36 (8 domain scores and 2 component scores) , WPAI , 
EuroQol EQ -5D and the FACI T-Fatig ue scale score, respectivel y, from Week 24 to 
Week 48 and from W eek 24 to Week 36;
HAQ- DI respons e(ie, decrease of at least 0.22) at Weeks 48 and 36.
[IP_ADDRESS]. Other Efficacy Endpoints
Change sin DAS28-4 (ESR), DAS28-4 (CRP), CDAI, SDAI, HAQ -DI, 
SF-36 (8 domain scores and 2 component scores ), WPAI , EuroQol EQ -5D score and 
FACI T-Fatigue scale score , respectivel y,from day 1to Week 12 and from Day 1to 
Week 24;
LDA as assessed b y DAS28 -4(ES R)3.2, DAS28- 4(CRP)3.2,CDAI10and 
SDAI11, respectively , at Weeks
12and 2 4;
Remission as assessed by [CONTACT_104706] -EULAR Boolean remission criteria, 
DAS 28-4 (ESR)<2.6, DAS28 - 4 (CRP)<2.6, CDAI 2.8and SDAI3.3, respectively ,
at W eeks 12 and 24;
ACR20, ACR 50, and ACR70 response s, respectively ,at W eeks 12 and 24 ;
HAQ- DI response (ie, decr ease of at least 0.22) at Weeks 12 and 24;
Changes in tender/painful joint counts, swollen joint counts , subject assessment of 
arthritis pain, subject global assessment of arthritis, phy sician global assessment of 
arthritis, and CRP, respectively , from day 1to Week 12 and from day  1to Week 24 , 
from Week 24 to Week 48 and from week 24 to Week 36 .
[IP_ADDRESS]. Safety Endpoints
All adverse events (AEs), including serious adverse events (SAEs) ;
Clinically  significant abnormal laboratory  para meters
.
[IP_ADDRESS]. Exploratory Endpoints
Exploratory  biomarker/genomics endpoints will be specified in a separate protocol 
and/or statistical anal ysis plan if exploratory  analyses utilizing the bio -banked 
exploratory  genomic and biomarker samples across tofacitinib studies or across 
multiple prog
rams are conducted;

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, 04 Dec 2017
Page 25US and Canada ONLY : RAPI D3summary  score sat Weeks 12, 24, 36 and 48.
3.STUDY DESIGN
Study  A3921192 is a 12- month randomized, double -blind, placebo -controlled withdrawal 
study  in a total of approximately  580 subjects with moderate to seve re RA (defined as CDAI 
>10and DAS28 (ESR)  3.2) who are insufficiently  responding to their stable dose of MTX 
treatment.
  The enrollment will be monitored by  [CONTACT_167160]  50% of 
enrolled subjects will have moderate disease activity  (defined as 
DAS28 (ESR)  3.2and 
5.1) and 
approximatel y 50% will have severe disease activity  (defined as DAS28 (ESR) .In 
addition, the proportion of subjects who have had an insufficient response to one or more 
biologics prior to the enrollment should be 25% (ie, 145subjects).
After reviewing the rate of achievement of LDA and monitoring the discontinuation rate in 
the op
en-label period, the decision was made to increase in enrollment numbers from 
approximatel y 580to 680 factoring in a discontinuation r ate of approximately  15% during 
the open label run -in phase .  As of 02 Aug 2017, study  was 50% enrolled with 81% having 
severe disease activity .  The LDA rate (~79% based upon a small sample size) was higher 
than protocol assumptions and historic data.  It is expected that enrolling >50% of subjects 
with severe disease activity  will result in a sufficient n umber of subjects with L DA at Week 
24.  Therefore , the enrollment requirement of 50% of subjects with severe disease activity  
and 50% with moderate disea se activity was removed from the protocol .
Following enrollment, all subjects will receive open- label tofacitinib MR 11mg QD added to 
MTX at their previousl y stabilized dose for 24 weeks (run- in phase). At the end of the run -in 
phase ( Week 24), only  subje cts who achieve low disease activity  (LDA) as assessed b y 
CDAI  (ie, CDAI ≤ 10) (approximately  232 subjects) will be randomized into the 24 -week 
double -blind, placebo -controlled MTX withdrawal phase. Subjects who do not achieve LDA 
(defined b y CDA I >10) at this time point will be discontinued from the study.   Subjects 
entering the double -blind phase will be randomized in a 1:1 ratio to either continue the run -in 
phase treatment regimen (tofacitinib MR 11mg QD with blinded MTX) or to receive 
tofacitinib monot herap y (tofacitinib MR 11mg QD with blinded matching placebo for MTX).  
Randomization will be stratified b y subject’s prior exposure to a biologic DMARD.   
Randomized subjects will be followed up to the end of Week 48.  The primary  efficacy  
endpoint is the 
change in DAS28-4 (ESR) from randomization (at Week 24) to the end of 
double -blind MTX withdrawal phase (at Week 48).

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, [ADDRESS_194335] eligibility  should be reviewed and documented by  [CONTACT_4653]’s study  team before subjects are inc luded in the study .
Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the 
study :
1.Evidence of a personally  signed and dated informed consent document indicating that 
the subject has been informed of all pertinent aspects of the study .
2.Subject sarewilling and able to comply  with scheduled visits, treatment plan, 
laboratory  tests, and other study  procedures .
3. Must be 18 years of age or older.Week 24 
  (Day 168)
Randomization (1:1) 
Baseline
(Day 1)Week 6
(Day 42)Tofacitinib MR 11m g QD + MTX
Tofacitinib MR 11m g QD + MTX
Week 48 ([ADDRESS_194336] -
randomization) (Day 336)  Open - label 
(Run -in phase)       MTX withdrawal
(Double -blind ph ase)
Week 36
(Day 252)
Prim ary Endpoint: 
ΔDAS28 -4(ESR) 
(Week 48 –Week 24)
Randomization Criteria :
CDAI -defin ed LDA
(CDAI ≤10)
Screening
(Day -30)Screening     Tofacitinib MR 11m g QD + placebo for 
MTX  
Week 12 
(Day 84)

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, [ADDRESS_194337] a score of 6 or greater on the 2010 American Colle ge of 
Rheumatology /European L eague Against Rheumatism Classification Criteria for 
Rheumatoid Arthritis at 
and/or prior to Screening Visit . 
5.Have4tender/painful joints on motion and 4swollen joints (28 joint counts) at 
both Screening Visit and Baseline Visit (Visit 1) .
6.
Have moderate to severe disease activit yas defined by [CONTACT_82274] > 10 and DAS28- 4(ESR)
3.2at Baseline Visit . 
7.Have taken an oral MTX treatment regimen (15-25mg/week) continuousl y for at least 
4months prior to the screening visit and has taken a stable weekly do se of oral MTX 
with supplemental folic acid or foli nic acid for at least 4 weeks prior to the baseline 
visit (conversion from parenteral MTX to oral MTX will require stabilization of the 
treatment regimen for at least 1month ):
MTX doses between 10mg/week and <15mg/week are allowed onl y if there is 
documented intolerance or toxicity  from higher doses in the source 
documentation .
MTX doses less than 10mg/week or more than 25mg/week are not permitted 
under an y circumstances.
a.Must receive either folic acid (atleast 5 mg weekly ) or folinic acid (at least 
2.5mg weekl y) as folate supplementation according to local MTX label 
guidelines and standard of care. 
Subject smust have an inadequate clinical response to MTX ,defined as the 
presence of sufficient residual disease activity  to meet the entry  criteria.
8.Male subjects able to father children and female subjects of childbearing potential and 
at risk for pregnancy  must agree to use [ADDRESS_194338] negative for pregnancy at 
screening 
visit and baseline visit. 
10. Female subjects who are not of childbearing potential (ie, meet at least 1 of the 
following criteria):
Have undergone a documented hy sterectomy  and/or bilateral oophorec tomy ;
Have medically  confirmed ovarian failure; or 

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, 04 Dec 2017
Page 28Achieved postmenopausal status, defined as follows: cessation of regular menses 
for at least 12 consecutive months with no alternative pathological or 
physiological cause; and have a serum follicle -stimul ating hormone (FSH) level 
confirming the post- menopausal state .
All other female subjects (including females with tubal ligations) will be 
considered to be of childbearing potential.
11.Subjects must screen negative for active tuberculosis or inadequatel y treated 
tuberculosis infection (active or latent) as evidenced by  [CONTACT_3959]:
a.Negative QuantiFERON GoldIn-Tube test performed at screening:
This is required unless the subject has been adequately  treated for active or 
latent tuberculosis or a neg ative QuantiFERON GoldIn-Tube test was 
previously  performed and documented within the 3 months prior to 
screening.
A negative tuberculin skin test (TST) is one that is <[ADDRESS_194339] ituted for the QuantiFERON GoldIn-Tube test onl y if the 
central laboratory  is unable to perform the test or the test is reported as 
indeterminate after at least 2 succes sive attempts.
Itis strongl y recommended that subjects with a history  of Bacille Calmette 
Guérin (BCG) vaccination be tested with the Qu antiFERON Gold
In-Tube test.
b.Chest radiograph (or chest Computed T omography (CT) scan, if available) 
taken at screening without changes suggestive of active tuberculosis (TB) 
infection, unless previously  performed and documented within 3 months prior 
to screening.
c.No history  of tuberculosis infection unless one of the following is 
documented:
Subject swith prior or current latent tuberculosis haveno evidence of 
active tuberculosis and must be taking or have completed an adequate 
course of therap y for lat ent tuberculosis in a locale where rates of primary  
multi- drug resistant TB infection are <5%, and chest radiograph s(or chest 
CT scan) arenegative for active disease; the chest radiograph must be 
obtained at screening or, if previously  performed and docu mented, within 
3 months prior to screening. 
Subject swith prior active tuberculosis has no current evidence of active 
disease and ha ve completed an adequate course of therap y for active 
tuberculosis (a multi- drug regimen recognized by  [CONTACT_67848]) and chest radiographs (or chest CT scan) are negative for 

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, 04 Dec 2017
Page 29active disease; the chest radiograph must be obtained at screening or, if 
previously  performed and documented, within 3 months prior to 
screening.
4.2. Exclusion Criteria
Subjects with any  of the following characteristics/conditions will not be included in the 
study :
1.Subjects who are investigational site staff members directl y involved in the conduct 
of the study  and their family  members, site staff members otherwise supervised by  [CONTACT_167167], or subjects who are [COMPANY_007] emplo yees directly  involved in the conduct of 
the study .
2.Pregnant female subjects; breastfeeding female subjects; male subjects with partners 
currentl y pregnant; male subjects able to father children and female subjects of 
childbearing potential who are unwilling or unable to use [ADDRESS_194340].  F or contraception det ails 
to be applied in Belgium, Czech Republic, [LOCATION_013] , Hungary , Italy, Poland, Spain, 
and the [LOCATION_008] see Appendix 7.
3.Subjects with any  of the following infection or infection history : 
a.Any infection requiring treatment within 2 weeks prior to the Baseline Visit
(Visit
1).
b.Any infection requiring hospi[INVESTIGATOR_059], parenteral antimicrobial therapy , or as 
otherwise judged to be an opportunistic infection or clinically  significant by  [CONTACT_1275], within the past 6 month s.
c.Infected joint prosthesis at an y time with the prosthesis still in situ.
d.Recurrent (more than one epi[INVESTIGATOR_1865]) herpes zoster or disseminated (a single 
epi[INVESTIGATOR_1865]) herpes zoster or disseminated (a single epi[INVESTIGATOR_1865]) herpes simplex.
e.Subjects will be screened for hu man immunodeficiency  virus (HIV).  Subjects 
who test positive for HIV will be excluded from the study .
f.Subjects will be screened for hepatitis B virus infection.   Subjects with hepatitis B 
surface antigen (HBsAg) negative testing but who test positive for hepatitis B 
core antibod y (HBcAb) must have further testing for hepatitis B surface antibody 
(HBsAb).   If HBsAb is negative, the subject will be excluded from the study .

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, 04 Dec 2017
Page 30g. Subjects will be screened for hepatitis C virus antibodies (HCV Ab).  Subjects 
with p ositive HCV Ab tests will be reflex tested for hepatitis C virus ribonucleic 
acid (HCV RNA).  Only subjects with negative HCV Ab or HCV RNA will be 
allowed to enroll in the study .
h. Subjects are excluded for current active tuberculosis infection or prior act ive or 
latent tuberculosis that was inadequatel y treated or where adequate treatment 
cannot be documented.
i.Subjects screened in Belgiu m, Czech Republic, German y, Hungary , Italy, Poland, 
Spain, 
and the [LOCATION_008] who have resided or traveled in areas wi th 
endemic tuberculosis or endemic m ycoses will be excluded .
4.Subjects with any  current malignancy or a history  of malignancy , with the exception 
of adequately  treated or excised non -metastatic basal cell or squamous cell cancer of 
the skin or cervical carc inoma in situ.
5.Subjects with any uncontrolled clinically  significant laboratory  abnormality or any  of 
the following laboratory abnormalities:
a.Evidence of hematopoietic disorder or hemoglobin <9 g/dL ;
b. White blood cell count <3.0 x 109/L (<3000/mm3);
c.Absolute ly mphocy te count < 0.5x 109/L (<500/mm3) ;
d.Absolute neutrophil count < 1.0 x 109/L (<1000/mm3) ;
e.Platelet count <100 x 109/L (<100,000/mm3);
f.Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >1.5 times 
the upper limit of normal (x ULN) ;
g.Estimated glomerular filtration rate (GFR) <40 mL/min using the Cockcroft- Gault 
formula.
6. Subjects with a history  of insufficient response to ≥2biologics, regardless of the 
class .
7. Participation in other studies involving investigational drug(s) within 4 weeks or 
5half-lives (whichever is longer) after discontinuation of the investigational 
compound prior to the current stud y entry and/or during study  participation, unless 
further restrictions to class of compound are specified in Section 4.2 (exclusion 
criteria) and Section 5.8 (concomitant treatment ).
8.Subjects requiring or have received an y prohibited concomitant medication as 
outlined in Appendix 3: Prohibited Concomitant Medication , including:

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, [ADDRESS_194341] previously  been treated with tofacitinib , baricitinib, or any  
other 
investigational JA K inhibitors .
c.Subjects who are being treated with biologic or non -biologic DMARDs (including 
antimalarials) other than MTX within their specified washout window at study  
entry  (defined in Appendix 3: Prohibited Concomitant Medications , and 
Section5.8.2: Disallowed Concomitant Medications ).
d.Subjects who are being treated with corticosteroids, other than stable 
low dose 
oral corticosteroids in doses equivalent to 10mg prednisone per day , within 
4weeks prior to th e first dose of the study  drug.
e.Subjects who require concomitant treatment with medications that are potent 
inhibitors of cy tochrome P450 3A4 (CYP3A4), both moderate inhibitors of 
CYP3A4 and potent inhibitors of CYP2C19, or potent CYP 3A4 inducers (defined
in Appendix 3: Prohibited Concomitant Medications).
9.
Subjects with a screening 12-lead electrocardiogram that demonstrates clinically 
significant abnormalities requiring urgent treatment (eg, acute m yocardial infarction, 
serious tach y-or brady arrhy thmias) or that is indicative of serious underl ying heart 
disease (eg, cardiomy opathy , major congenital heart disease, low voltage in all leads).
10. Subjects who had significant trauma or surgical procedure within 1 month prior to the 
Baseline Visit (Visit 1).
11.Subjects with any  rheumatic autoimmune disease, other than RA and Sjogren’s 
syndrome.
12. Subjects who are classified Class IV of the ACR 1991 Revised Criteria for Global 
Functional Status in RA (ie, are limited in their ability  to perf orm usual self -care, 
vocational, and avocational activities).
13.Subjects with ly mphoproliferative disorders (eg, Epstein Barr Virus (EBV) related 
lymphoproliferative disorder), a history  of lymphoma, leukemia, or signs and 
symptoms suggestive of current l ymphatic disease.
14.Subject s with history  of, or current evidence for, severe gastrointestinal narrowing
(pathologic or iatrogenic );eg,esophageal motility  disorders, “short gut” s yndrome 
due to adhesions or decreased transit time, past history  of peritonitis, chronic 
intestinal pseudoobstruction, or Meckel’s diverticulum .

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, [ADDRESS_194342] 
inappropriate for entry  into this study .
4.3. Randomization Criteria 
All eligible subjects enrolled in the study  will initially  receive open- label tofacitinib 
combined with MTX for 24 weeks (run-in phase) .  At the end of the 24-week open -label
run-in phase, onl y subjects who achieve Low Disease Activ
ity (LDA) (as assessed by [CONTACT_82274] 
≤10) will be randomized to the 24- week double -blind, placebo -controlled , MTX withdrawal 
phase.  Subjects who do not achieve the LDA ( as assessed b yCDAI>10) at this time point 
will b e discontinued from the study .
Subjects who enter the 24- week double -blind phase will be randomized in a 1:1 ratio to 
either continue the run -in phase treatment (tofacitinib MR 11mg QD with blinded MTX) or 
to receive tofacitinib monotherap y (tofacitinib MR 11mg QD with blinded placebo for MTX. 
Randomization will be stratified b y whether or not the subject was ever exposed to a biologic 
DMARD previously .
4.4.Lifestyle Guidelines 
4.4.1. Non-Pharmacologic Interventions
The subject may  continue all non -pharmacologic therapi[INVESTIGATOR_014], such as phy sical therap y, as 
indicated and deemed appropriate for his/her ph ysical condition.
4.4.2. Vaccine and Exposure to Infections Guidelines
It is recommended that subjects be up to date on all recommended vaccination (including 
pneumococcal vaccine and flu vaccine) per local practice gui
deline prior to enrollment .
Vaccination with live components is prohibited within the 4weeks prior to first dose of 
investigational product to 6weeks after last dose of investigational product.  In addition, 
current routine household contact [CONTACT_167168] a risk during treatment and for 6 weeks following 
completion of the study .  Some of these vaccines include adenovirus Ty pe 4 &Type 7, BCG, 
Dengue Fever, measles, mumps, rubella, varicella (“chickenpox”) vaccine or varicella -zoster 
vaccine , oral polio v accine, rotavirus, Yellow Fever and the intranasal (inhaled )flu vaccine. 

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, [ADDRESS_194343] been vaccinated with live vaccine components should be avoided following 
their vaccination with the following vaccines for the stated time period:
Attenuated t yphoid fever vaccination for 4 weeks following vaccination;
Oral polio vaccination for 6 weeks following vaccination;
Attenuated rotavirus vaccine for 10 days following va ccination;
FluMist(intranasal flu vaccine) for 1 week following vaccination.
4.4.3. Dietary Supplements
For the purposes of this protocol, dietary supplements are defined as vitamins, minerals, 
purified food substances, and herbals with pharmaceutical properti es.
Vitamins, minerals and purified food substances are allowed in amounts not known to be 
associated with adverse effects (such as h ypervitaminosis). 
Herbals with pharmaceutical properties are allowed only  if there is acceptable evidence of no 
potent CYP 3A4 inhibition or induction, or both moderate CYP3A4 and potent CYP2C19
inhibition.  Otherwise, herbals with pharmaceutical properties must be discontinued for at 
least [ADDRESS_194344], unless there is sufficient data 
available regarding the duration of an herbal m edication’s pharmacokinetic and 
pharmacod ynamic effects to allow a shorter washout to be specified (eg, 5 half-lives). 
Subjects must receive either folic acid (at least 5 mg weekl y) or folinic acid (at leas t 2.5 mg 
weekl y) as folate supplementation according to local MTX label guidelines and standard of 
care. 
4.4.4. Surgery
During the course of this study , no elective surgery  should be scheduled without first 
consulting with the [COMPANY_007] study  clinician.   Preferabl y, elective surgery  should be scheduled 
before the study  entry  or delay ed until participation in the study  is completed.
It is recommended that subjects who require major surgery  temporaril y discontinue 
tofacitinib approximatel y 1week prior to the surgica l procedure and remain off tofacitinib
after the surgical procedure until sutures/staples are removed. Investigational products can 
be resumed when the sutures/staples are removed.  If absorbing sutures or chemical closure 
methods are utilized, investigat ional product can be resumed when the operative site is 
sufficiently  healed and risk of infection is minimal.

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, 04 Dec 2017
Page 344.4.5. Contraception and Reproductive Status
In this stud y, male subjects who are able to father children and female subjects who are of 
childbearing pot ential will receive MTX , which has been ass ociated with teratogenic risk , 
and tofacitinib , which has been associated with teratogenic risk in animals (further 
information can be found in the single safet y reference document) .  Those who, in the 
opi[INVESTIGATOR_13046], are sexuall y active and at risk for pregnancy with their partner(s) 
must agree to use with their partner(s) two (2) methods of highly  effective contraception 
throughout the study  and continue for at least 3months after the last dose.  Th e investigator
or his or her designee , in consultation with the subject, will select 2appropriate methods of 
contraception for the individual subject and his/her partner (s)from the list of permitted 
contraception methods (see below) and instruct the subj ectin their consistent and correct use.  
The investigator or his or her designee will discuss with the subject the need to use [ADDRESS_194345]’s affirmation, in the subject’s 
chart.   In addition, the investigator or his or her designee will instruct the subject to call 
immediately  if a selected contraception method is discontinued or if pre gnancy  is known or 
suspected in the subject or the subject’s partner. 
Highly  effective methods of contraception are those that, alone or in combination, result in a 
failure rate of less than 1% per year when used consistently  and correctly  (ie,perfect us e) and 
include the following:
1.Established use of hormonal methods of contraception associated with inhibition of 
ovulation (ie, oral, inserted, injected, implanted, transdermal) provided the subject (or 
the subject’s partner(s)) plans to remain on the same treatment throughout the entire 
study  and has been using that hormonal contraceptive for an adequate period of time 
to ensure effectiveness.
2.Correctl y placed copper -containing intrauterine device (IUD )or intrauterine sy stem .
3.Male condom or female con dom u sed WI TH a spermicide (ie, foam, gel, film, cream, 
or suppository ).For countries where spermicide is not available or condom plus 
spermicide is not accepted as highly effective contraception, this option is not 
appropriate.
4. Male sterilization with absenc e of sperm in the postvasectomy  ejaculate .
5.Bilateral tubal ligation / bilateral salpi[INVESTIGATOR_8820] y or bilateral tubal occlusive procedure 
(provided that occlusion has been confirmed in accord ance with the device’s label).
Pregnancy  testing w ill be performed and documented at every  visit unless the 
non-childbearing potential is confirmed and documented .  The specific contraceptive 
methods will be documented and at every  visit, their consistent and correct use will be 
ascertained and documented in the subject’s c ase report form.

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, 04 Dec 2017
Page 35For contraception an d reproductive status details to be applied in Belgium, Czech Republic, 
German y, Hungary, Italy, Poland, Spain, and the [LOCATION_008] see Appendix 7.
4.5.Sponsor ’sQualified Medical Personnel
The contact [CONTACT_1133]'s appropriately
 qualified medical personnel for the 
study  is documented in the study  contact [CONTACT_167169] y qualified medical personnel on stud y
-related medical 
questions or problems, subjects are provided with a contact [CONTACT_1137]. The contact [CONTACT_4662], 
at a minimum, protocol and investigational compound identifiers, subject study  numbers, 
contact [CONTACT_4663], and contact [CONTACT_4664] a contact [CONTACT_128647] a medical 
question or problem originating from another healthcare professional not involved in the 
subject’s participation in the study .The contact [CONTACT_167170]; however, it should be used
only in the event that the established communication pathway s between the investigational 
site and the study  team are not available. It is therefo
re intended to augment, but not replace, 
the established communication pathway s between the investigational site and the study  team 
for advice on medical questions or problems that may  arise during the study .The contact 
[CONTACT_8865] b y the subject directly , and if a subject calls that number, he 
or she will be directed back to the investigational site.
4.6.Rater Qualifications 
A Joint Count Assessor blinded to subject data (including adverse events, subject reported 
outcomes and ph ysician a ssessments of disease activity  and/or severity ) will assess the 
number of swollen and tender/painful joints, as part of the assessment of RA activity .  The 
Joint Count Assessor at each site is required to be a health care professional who has been 
trained 
in rheumatolog y and specializes in the treatment of subjects with rheumatoid arthritis 
or has experience in conducting at least 20 joint count assessments in clinical trials or has 
been trained b y a health care professional and conducted over 20 supervised joint count 
assessments. 
5.STUDY TREATMENTS
For the purposes of this study , and per International Conference on Harmonization ( ICH )
guidelines investigational product is defined as a pharmaceutical form of an active ingredient 
or placebo being tested or used as a reference in a clinical trial, including a product with a 
marketing authorization when used or assembled (formulated or packaged) in a way  different 
from the approved form, or when used for an unapproved indication, or when used to gain 
further information about an approved use (ICH E6 1.33).  Tofacitinib and MTX are 
investigational products in this study . 
All subjects enrolled in the study  will initially  receive open
-label tofacitinib andMTX for 
24weeks (run- in phase).  Subjects who achieve LDA (as assessed b y CDAI ≤10) at the end 
of the run-in phase will be randoml y allocated (in a 1:1 ratio) to either tofacitinib with 
continued MTX arm or tofacitinib with placebo arm as presented in Table 1.

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, 04 Dec 2017
Page 36Table 1. Treatment A rms
Open -label phase (all subjects)
One tablet open -label tofacitinib MR 11mg orally QD + open -label MTX capsule(s) orally every week at 
prior stabilized dose
Double -blind phase (subjects will be randomized to one of the two arm s below ) 
Arm  1(tofacitinib MR 11m g QD with blinded MTX):One tablet open -label tofacitinib 11 mg orally QD 
+ blinded MTX capsule(s) orally every week at prior stabilized dose
OR
Arm  2(tofacitinib MR 11m g QD with blinded placebo for MTX, ie , tofacitinib MR 11mg QD 
monotherapy): One tablet open -label tofacitinib 11 mg orally QD + blinded matching p lacebo capsule(s) for 
MTX orally every week at prior stabilized dose 
5.1.Allocation to Treatment
Allocation of subjects to treatment arms will proceed through the us e of an automatic 
Interactive W eb-based R esponse (IWR) system provided by  [CONTACT_1034].  There is a 
24-hour-a- day, [ADDRESS_194346] informat ion and further details 
on the use of the IWR system. 
At the s creening visit, the site personnel (stud y coordinator or specified designee) will enter 
the subject into the I WR by  [CONTACT_167171] (eg, the date of birth and initials of the subject ) and receive the unique 
subject i dentification (ID) number generated b y the I WR for each subject .  The subject who 
is failed to pass the screening will not be enrolled into the study .  The subject who passes the 
screening will be enrolled into the study  and assigned with the open -label treatments .
Following the 
confirmation of LDA status at the end of the run -in phase , the site personnel
will be required to enter or select information including but not limited to the prot ocol 
number, the subject ID number, the 
date of birth and/or initials of the subject ,the LDA status 
and the prior use of biologic DMARDs in the I WR.The site personnel will then be provided 
with a treatment assignment code which corre sponds to the number on the dispensable unit 
(DU) or container in the site’s inventory .  The corresponding DU or container will be 
dispensed to the subject.   The I WRsystem will provide a confirmation report containing the 
subject number and DU or containe r number assigned. The confirmation report must be 
stored in the site’s files.
5.2.Breaking the Blind 
This study  will be subject -
, investigator- , and sponsor -blinded.  At the initiation of the study , 
the study  site will be instructed on using IWRfor breakin g the blind.  The blind should only  
be broken in emergency  situations for reasons of subject safet y.  Whenever possible, the 

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, [ADDRESS_194347] be fully  documented and entered on the case 
report form (CRF) .  At all other times, treatment and randomization information will be kept 
confidential and will not be released to the investigator/study  staff until the conclusion of the 
study .
5.3.Subject Compliance
Compliance with expected consumption of dispensed investigational product will be assessed 
by [CONTACT_167172] y given time period , keepi[INVESTIGATOR_167139] y withheld due to abnormal laboratory  tests, adverse events, or the need to 
take a short course of a prohibited concomitant medication.  Doses of investigational 
product snot taken during these events do not constitute protocol deviations and should not 
be considered dosing errors, but should be noted in the dosing log on the CRF 
with the 
reason for reduced drug consumption. 
Compliance of less than 80% of the expected number of doses for an y one of the 
inves tigational products in the interval should be documented in the dosing log of the 
subject’s CRF with the reason for non -compliance (less than expected consumption) , and 
should be reported as a protocol deviation , and unless there is a protocol stipulated r eason for 
non-compliance with the dosing regimen, this should be recorded as a dosing error.  Subjects 
who are less than 80% compliant with the dosage regimen for an
y two consecutive visit 
periods during the study  should be withdrawn from the study .
Compli ance of more than 120% of the expected number of doses for any one of the
investigational products in the interval should be documented in the dosing log o f the 
subject’s CRF with the reason for non- compliance (more than expected consumption) , and 
should b
e reported as a protocol deviation and recorded as a dosing error. 
Subjects who are non -compliant will be counseled and the site will implement appropriate 
measures to secure subject compliance, as appropriate to the site and reason for 
non-compliance.
Subjects will record all Tofacitinib and MTX dosing in a dosing diary .  It will be reviewed 
with the subject at every  study  visit for compliance .
5.4.
Investigational Product Supplies
5.4.1. Dosage Form(s) and Packaging
During the run -in phase, tofacitinib citrate MR 11mg tablets and MTX 2.5 mg capsules will 
be provided in open- label bottles for oral administration by [CONTACT_2728].  During the 
double -blind phase, open -label bottles of tofacitinib MR 11mg tablets and blinded bottles of 
MTX 2.5mg capsules or matching placebo capsules for MTX will be provided for oral 
administration by  [CONTACT_2728] . 

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, 04 Dec 2017
Page 385.4.2. Preparation and Dispensing
At each dispensing visit ( Baseline Visit/Visit 1 , and Visits 3, 4 and 5 ), subjects will receive a 
sufficient quantity  of investigational product sto last unti l their next scheduled dispensing
visit plus an additional amount to accommodate the allowable visit windows . Investigational 
product s
, along with written dosing instructions (dosing cards), will be dispensed by [CONTACT_160440] y qualified and experienced member of the study  staff (eg, phy sician, nurse, 
physician’s assistant, practitioner, or pharmacist) as allowed by  [CONTACT_5737], state, and institutional 
guidance.   The amount of investigational products dispensed at each visit must be recorded.
Only  qualified pe rsonnel who are familiar with procedures that minimize undue exposure to 
them and to the environment should undertake the preparation, handling, and safe disposal of 
chemotherapeutic agents.
5.5.Administration
All investigational product
s will be self- administ ered b y the subject as specified in the dosing 
card with written instructions. 
Investigational product s may  be taken with or without food, other than on study  visit day s 
where fasting is required.  Subjects will swallow the investigational product whole and intact , 
and will not manipulate (eg, crush or split) or chew the medication prior to swallowing.
Subjects will take their tablets (tofacitinib) once daily in the morning, and take their capsules 
(MTX or matching placebo for MTX) once a week (the same da y of the week and 
approximatel y the same time each week) unless dose division is required to manage 
intolerance. 
At the beginning of the enrollment (ie, baseline visit/visit 1), subjects must discontinue the 
use of their personal (commercial) suppl y of MT X.  All tofacitinib and MTX drug supplies 
will be provided by  [CONTACT_167173]. 
All subjects entering the study  must have taken MTX continuously  for at least [ADDRESS_194348] 4 weeks 
prior to the baseline visit ( visit 1).  Dosages of MTX (oral administration of up to 
25mg/week) are as approved in the respective Single Reference Safet y Document (SRSD), 
as identified in Section 1.2.4 of this protocol. MTX doses between 10mg/week and
15mg/week are allowed only in the presence of documented intolerance to or toxicity  from 
higher doses in the source documentation .  Doses l ess than 10 mg/week o rmore than 
25mg/week are not permitted under an y circumstances.  The pre -study  stable dose of MTX 
will be continued in the study  period. The dose of MTX or matching placebo for MTX will 
be maintained throughout study  particip ation unless dose reductions arefurther required due 
todrug toxicity .Dose reductions will be documented in the CRF.
Subjects who are randomized to placebo forMTX arm will re ceive full withdrawal of MTX 
(ie, no tapering) at the time of randomization.

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, [ADDRESS_194349] of care practices for the administration of MTX include: laboratory  
testing, follow up care, contraindications, and folate supplementation.  MTX laboratory  
testing is ty pi[INVESTIGATOR_167140]  3months once a subject is stabilized on MTX. However, in some 
regions, more frequent MTX testing and procedures are required; therefore MTX tests and 
procedures should be performed according to local standards of care throughout the study , 
regardless of study  assignment.   Subjects must receive eithe r folic acid (at least 5 mg weekl y) 
or folinic acid (at least 2.5 mg weekl y) as folate supplementation according to local MTX 
label guidelines and standard of care. 
5.6.
Investigational Product Storage 
The investigator, or an approved representative, eg, phar macist ,will ensure that all 
investigational products, including any  marketed products, are stored in a secured area with 
controlled access under re quired storage conditions and in accordance with applicable 
regulatory  requirements.
The investigational dru g product should be stored in its original container and in accordance 
with the label.  See the dosing card for storage conditions of the product. Storage conditions 
stated in the single reference safet y document (SRSD) (tofacitinib I B and MTX SPC revised
December 2012) will be superseded b y thestorage conditions stated in the labeling.
Site sy stems must be capable of measuring and documenting (for example, via a log), at a 
minimum, daily  minimum and maximum temperatures for all site storage locations (as
applicable, including frozen, refrigerated and/or room temperature products).  This is to be 
captured from the time of investigational product receipt throughout the study .  Even for 
continuous monitoring sy stems, a log or site procedure that ensures acti ve daily  evaluation 
for excursions should be available .  The operation of the temperature monitoring device and 
storage unit (for example, refrigerator), as applicable, should be regularl y inspected to ensure 
it is maintained in working order. 
Any excursi ons from the product label storage conditions are to be reported upon discovery .  
The site should activel y pursue options for returning the product to the 
storage conditions as 
described in the labeling , as soon as possible.  Deviations from the storage re quirements, 
including any  actions taken, must be documented and reported to the sponsor. 

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, [ADDRESS_194350] supplies.   At each stud y visit (except baseline
/visit1 and Week 6 /Visit 2), the subject must return the containers of investigational product s 
to the investigator and the amount of an y unused medications will be recorded.   To ensure 
adequate records, all drug supplies will be accounted for in the drug accountability  inventory  
forms and will be monitored b y the accounting of unused investigational product
sreturned
by [CONTACT_748] .
5.7.1. Destruction of Investigational Product Supplies 
The sponsor or designee will provide guidance on the destruction of un used investigational 
product (eg, at the site). If destruction is authorized to take place at the study  site, the 
investigator must ensure that the materials are destroy ed in compliance with applica ble 
environmental regulations, institutional policy , and any  special instructions provided by  
[CONTACT_4618] ,and all destruction must be adequatel y documented.
5.8.Concomitant Treatment(s)
All concomitant medication taken during the stud y must be recorded with the ge neric name 
[CONTACT_11889], reason for administration, dose and frequency , route of administration and 
start and stop dates in the subject’s case report form.  A subject who is receiving an allowed 
concomitant medication for an y reason should be on a loc ally approved medication and a 
dose that is considered standard of care for the treated indication. 
Medications taken after informed consent but before the first dose of investigational product s 
will be documented as prior medications.   Medications taken after the first dose of 
investigational product
s will be documented as concomitant medications.

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, 04 Dec 2017
Page 415.8.1. Allowed Concomitant Medications
All concomitant DMARDs including antimalarials are excluded at Baseline Visit/V isit 1 , 
except MTX. 
[IP_ADDRESS]. Treatment for Latent Tubercu losis
Subjects who are diagnosed as having latent tuberculosis (ie, positive tuberculosis test, chest 
x-ray or CT negative for active tuberculosis, and no evidence of active disease) at screening 
must have either been previously  treated with an adequate co urse of treatment or be currentl y 
taking isoniazid.  Subjects that the investigator considers to be at high- risk to develop 
tuberculosis (eg, residing in high -
risk areas or travel to high- risk areas) may be started on 
isoniazid treatment at the discretion of the 
investigator.  When indicated, isoniazid treatment 
is required to be administered orally  at 300 mg/day  for a total of [ADDRESS_194351]’s case report form.  If an alternate treatment 
regimen is i mplemented, the reason for this must be documented and a cop y of the local 
standard of care guideline identify ing such treatment must be provided to the study  team.  
Within approximately  one month of initiating treatment with isoniazid, the subject should 
have transaminase levels checked.  A subject may  enroll into the study  after at least one 
month of isoniazid therapy or per local guideline .
PLEASE NOTE: although commonly  used in the treatment of tuberculosis, rifampin, 
rifampi[INVESTIGATOR_2513], rifabutin and rifapente ne are prohibited concomitant medications in this study .
[IP_ADDRESS]. Stable Background Arthritis Therapy
Subjects will continue on their stable background arthritis therap y, which can include
nonsteroidal anti -inflammatory  drugs ( NSAIDs), selective cy cloox ygenase - 2inhibitors 
(COX -2 inhibitors), opi[INVESTIGATOR_2438], acetaminophen, and/or low dose oral corticosteroids ( 10mg 
prednisone or equivalent per day ) throughout the trial.  Dosages of
NSAIDs/ COX -[ADDRESS_194352]’s safety.  However, the 
total daily  dose of acetaminophen may  not exceed the locally approved recomm ended dail y 
dose, and the total dail y dose of opi[INVESTIGATOR_167141] 30 mg o f 
orally -administered morphine ( Appendix 5: Approximate Equivalent Morphine Doses of 
Opi[INVESTIGATOR_36570]).   Please note that ad ministration of NSAIDs with MTX (usually  at high 
doses) can lead to serious adverse reactions including gastrointestinal and hematological 
toxicity .
Low dose oral corticosteroids in doses equivalent to ≤10mg prednisone per day  is allowed 
during the study  period.   However, the prednisone dose increase should not exceed the initial 
dose during the study  period .
Intra -articular corticosteroids may  be given during the first 3 months of the run -in phase in 
no more than two joints, in a cumulative dose of no more than 80 mg methy lprednisolone or 
its equivalent during an y 6month study  period.   Injections are not allowed after 3 months.   
Injected joints will also be considered as having their pre -
injection status (tender/painful or 
swollen) for the remainder of t he trial.

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, 04 Dec 2017
Page 42Intravenous or intramuscular corticosteroids are not allowed during this study .
Biologic DMARDs and non -biologic DMARDs ( other than MTX )are not allowed during 
this study .
5.8.2. Disallowed Concomitant Medications 
[IP_ADDRESS]. Disease Modifying Antirheumatic Drugs (DMARDs)
All DMARDs (except MTX) are disallowed during the study  period.   All prohibited 
concomitant DMARDs should be discontinued at least 4
weeks or 5 half-lives (whichever is 
longer) prior to the first dose of investigational product s (Baseline V isit/Vi sit 1) .  Specific 
medications and required discontinuation (washout) times are listed in Table 2.
Table 2. DMARDs –Required Washout Period
Required Washout Period Prior to Baseline/Visit 1
52weeks Ritux imab or other selective B lymphocyte depleting agents (both marketed and
investigational): discontinued for [ADDRESS_194353] sand if CD19/20+ counts are normal by [CONTACT_74064] -activated cell 
sorting ( FACS) analysis
20weeks Gold compounds, including auranofin (Ridaura),and injectable gold 
(aurothioglucose or aurothiomalate)
18weeks Canakinumab 
12weeks Abatacept, certolizumab pegol, tocilizumab
10weeks Golimumab 
8weeks Infliximab , leflunomide*
6weeks Adal imumab 
4weeks Anakinra, azathioprine, cyclosporine, etanercept,  tacrolimus, mizoribin, 
tetracycline, minocycline, penicillamine, sulfasalazine, bucillamine, chloroquine, 
hydroxychloroquine
* Leflunomide (Arava®) must be discontinued [ADDRESS_194354] dose of study drug: Cholestyramine at a dosage of [ADDRESS_194355] 24 hours (US PI,Elimination 
Procedure to significantly lower leflunomide drug levels).
[IP_ADDRESS]. Immune -Modulating Biologic Products
While receiving study  drug, no immune -modulating biologic products are allowed to be 
administered, including biologic DMARDs (except MTX) .
[IP_ADDRESS]. CYP3A4 and CYP2C19 Inhibitors and CYP3A4 Inducers
Tofacitinib exposure is increased when co- administered with medications that are potent 
inhibito rs of cy tochrome P450 (CYP) 3A4 (eg, ketoconazole) and medications that result in 
both moderate inhibition of CYP3A4 and potent inhibition of CYP2C19 (eg, fluconazole). 

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, 04 Dec 2017
Page 43Tofacitinib exposure is decreased when co -administered with potent CYP3A4 inducers (eg,
rifampin). 
To ensure sufficient washout of these effects on safet y and efficacy endpoints, drugs that are 
potent CYP3A4 and CYP2C19 inhibitors and drugs that are potent CYP3A4 inducers must 
be discontinued for at least 4weeks or 5half-lives (whichever is longer) prior to the Baseline 
Visit (V isit1).  Only  systemically  administered drugs listed in Appendix 3(Prohibited 
Concomitant Medication) require discontinuation; other routes of administration (eg, topi[INVESTIGATOR_2855], 
vaginal, op
hthalmic) are not prohibited. 
If a medication that is a potent CYP3A4 inhibitor or is both a moderate inhibitor of 
CYP3A4 and potent inhibitor of CYP2C19 is administered during the study for an y reason, 
including the treatment of an adverse event, tofacit inibshould be interrupted during 
treatment. 
If a medication that is a potent CYP3A4 inducer is administered during the study  for any  
reason, including the treatment of an adverse event, tofacitinib may be continued, but the 
concomitant administration of the medication should be noted as a protocol deviation.
[IP_ADDRESS]. Immunizations
Live or live -attenuated vaccines should not be given concu rrentl y with investigational 
product s (refer to Section 4.4.2 for more details).
[IP_ADDRESS]. Investigational medication
Any investigational medications must be discontinued prior to baseline visit (visit 1) for 
4weeks or 5 half-lives, whichever is longer.   No investigational compounds (other than 
tofacitinib and MTX ) may
 be taken during the study  period.
5.9.Rescue Medication
Please refer to Appendix 5(Approximate Equivalent Morphine Doses of Opi[INVESTIGATOR_36570]) 
and Appendix 6(Rescue Therap y) for details. 
6. STUDY PROCEDURES 
Please refer to Section 7 (Assessment) for details of exams and tests listed in this section. 
6.1.Screening
The study  investigator or a sub- investigator will discuss, with each subject, the nature of the 
study , its requirements, and its restrictions.  Written informed consent must be obtained prior 
to performance of an y protocol specific procedures.
Subjects will be screened 30 days (+10daywindow, ie, 40 days) prior to administration of
investiga tional product sto confirm that they  meet the entrance criteria for the study .  
Subjects must complete all screening procedures and assessments and have test results 
available prior to the baseline visit ( visit 1) .  If a subject is not enrolled within 30 days 
(+10 days window) 
after the screening visit, all screening procedures and assessment must be 

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, 04 Dec 2017
Page 44repeated unless otherwise noted (below) .  Sponsor approval must be obtained prior to 
re-screening a subject. 
Subjects who are on prohibited medications and ar e deriving a beneficial response from them 
should not be entered into th isstudy . However, there may  be subjects taking a prohibited 
medication who have experienced an ineffectual/ suboptimal response or side effect sand 
wish to enter the study .These subjects may require a washout period that extends bey ond 
the screening duration (See Section 5.8: Concomitant Medication and Appendix 3: Prohibited 
Concomitant Medic ation
).  For these subjects, written informed consent and the study  subject 
identification ( SSID) number must be obtained prior to initiation of the washout period .  The
screening assessments should 
be scheduled towards the end of the wash out period to mee t the
30-day (+10 days) screening duration.  Additionally , screening procedures may  need to be 
repeated to provide valid data (eg, laboratory  testing) and turnaround time may extend 
beyond the screening duration. In this case, sponsor approval must be obt ained.   In no 
instance should the extended screening duration exceed [ADDRESS_194356] all tests completed within screening period or who temporaril y do 
notmeet study  entry  criteria (eg, treatment with antibiotics during the screening per iod or for 
administrative reasons) may  be re-screen edone time; the subject’s prior ID number and 
reason for re -screening must be documented. 
Screening laboratory tests can be repeated once if deemed clinicall y appropriate (judged b y 
the principal investi gator) except for the following tests: positive hepatitis or HIV screen, 
positive QuantiFERON Gold®TMIn-Tube Test without adequate treatment, confirmed 
hemoglobin<9 g/dL , confirmed transaminases >1.[ADDRESS_194357].
Subjects, who do not meet screening criteria and /or do not re -screen, must be discontinued 
and the reason for screen failure must be documented in the CRF.
Subjects will continue their usual stable dose of MTX during the screening period.
Procedures to be performed during the screening period include:
Informed Consent.
Review of inclusion/exclusion criteria .
Prior Medications: this includes start dates and stop dates with reason for 
discontinuation (if appropriate), dosage and frequency of administration, and 
indication treated (make sure all indications are listed in the medical history) for all 
current medications, an y medications taken within the 4 weeks prior to screening 
procedures, and a complete history  of all DMARDs ever taken including the dates of 
administration and the reasons for discontinuati on. 
Medical History : include previous vaccination. 
Complete Phy sical Examination: height, weight, vital signs, general appearance, skin 
(presence of rash, skin lesions with malignant features ), HEENT (head, ey es, ears, 
nose and throat), lungs (auscultati on), heart (auscultation for presence of murmurs, 
gallops, rubs), lower extremities (peripheral edema), abdominal (palpation and 

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, 04 Dec 2017
Page 45auscultation), neurologic (mental status, station, gait, reflexes, motor and sensory  
function, coordination) and ly mph nodes.
Laboratory  testing (Blood Chemistry , Hematology , CRP, ESR, HI V Serology , 
HBsAg, HBcAb, HBsAb, HCV Ab, HCV RNA,  FSH (required to confirm 
postmenopausal status, if applicable ), Rheumatoid Factor, anti -cyclic citrullinated 
peptide antibodies (anti- CCP), Urina lysis.  All required laboratory  testing must be 
complete and reported ; any  invalid specimens must be retested and reported prior to 
the Baseline Visit (Visit 1). 
Pregnancy testing must be completed for all women of childbearing potential: all 
subjects mus t test negative; confirmation and documentation of the use of two highly  
effective methods of contraception b y subjects of childbearing potential or their 
partners must be done. Non childbearing potential must be documented.   For 
contraception an d reprodu ctive status details to be applied in Belgium, Czech 
Republic, German y, Hungary , Italy, Poland, Spain, and the [LOCATION_008] see 
Appendix 7.
QuantiFERON Gold®TMIn-Tube Test: unless the subject has previousl y received an 
adequ ate course of therapy  for either latent or active TB infection (see 
Section
[IP_ADDRESS]: Treatment for Latent Tuberculosis).
Chest x
-ray must show no evidence of active tuberculosis or other findi ng that would 
exclude the subject from the study  (see Section 7.3 :Chest Radiography ) .
12-lead electrocardiogram.
RA Activity : 28tender/painful and swollen joint counts performed and the numb
er of 
swollen joints and the number of tender/painful joints meet the criteria for inclusion.
Serious Adverse Event ( SAE) Reporting ( after the subject provides informed 
consent ).
Assess safet y events (ie, reportable s afety events within the appropriate rep orting 
period) for adjudication by  [CONTACT_167174].
6.2.Study Period
As part of advers e event monitoring, site personnel will assess safet y events for adjudication 
and potential malignancy events for biops y submission andcentral laboratory pathologist 
over read.  Specific safety  events will be submitted to the appropriate Safety  Event 
Adjudication/Review Committee for adjudication as described in Section 9.8. 
Sitepersonnel will report safet y events and potential malignancy events to the [COMPANY_007] Study 
Team or designee based on the following reference time points:

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, 04 Dec 2017
Page 46Events that are serious adverse events (SAEs) occurring after the time of informed 
consent will be submitted for adjudication/review or central histopathology  review, as 
appropriate.
Events that are non -serious AEs occu rring after the time of first dose of study  drug 
will be submitted for adjudication/review or central histopathology  review, as 
appropriate.
6.2.1. Visit Windows
The screening period is expected to be no longer than 30days(+ 10 day window) prior to the 
Baseline Visit (Visit 1), unless exceptions noted in Section 6.1 are documented.  All visits 
should be conducted as close to the scheduled visit day  as possible.  Exceptions may  be made 
to accommodate holiday s and unexpected events, such as weather- related site closures or 
illnesses requiring hospi[INVESTIGATOR_059].  I n these cases, the visit should be scheduled or 
re-scheduled as close to the original visit schedule as possible. 
All visits will contribute t o the dataset.   Visit 1 is the baseline visit; the visit window for Visit 
2 will be  5days; the visit windows for Visit 3 to V isit 6 will be 10days; and the visit 
window for telephone follow -up will be +14 daysto ensure capture of all data.
Partial an d unplanned visits (ie, those that do not include all required procedures) must be 
noted clearl y and the reason documented in the subject’s case report form.
6.2.2. Visit 1 ( Baseline Visit ; Day 1) 
At Visit 1 (Baseline Visit), subjects will convert their personal (commercial) supply  of MTX 
to the MTX supplied by  [CONTACT_167175].
Subjects are required to fast for at least 6 hours prior to the visit. 
Procedures to be performed at Baseline Visit /Visit 1 include:
Complete Phy sical Examination (excluding height) : weight, vital signs, general 
appearance, skin ( skin lesions with malignant features ), HEENT (head, ey es, ears, 
nose and throat), lungs (auscultation), heart (auscultation for presence of murmurs, 
gallop s, rubs), lower extremities (peripheral edema), abdominal (palpation and 
auscultation), neurologic (mental status, station, gait, reflexes, motor and sensory  
function, coordination) and ly mph nodes.  In addition, smoking history  and alcohol 
consumption will be documented.
Review of inclusion/exclusion criteria. 
Laboratory  testing including blood chemistry , hematology , CRP, lipid profile 
(fasting), ESR.
Biospecimen collection for banking.

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, 04 Dec 2017
Page 47Pregnancy  testing must be completed for all women of childbearing potential: all 
subjects must test negative; confirmation and documentation of the use of two highly  
effective methods of contraception b y subjects of childbearing potential or their 
partners must be done. Non childbearing potential must be documented.   For 
contraception an d reproductive status details to be applied in Belgium, Czech 
Republic, German y, Hungary , Italy, Poland, Spain, and the [LOCATION_008] see 
Appendix 7.
28
tender /painful and swollen joint count.
Completion of the following assessments:
Subject assessment of arthritis pain.
Subject global assessment of arthritis.
Physician global assessment of arthritis.
Health Assessment Questionnaire –Disability  Index ( HAQ DI ).
SF 36 (Version 2, Acute).
European Quality  of Life 5Dimension Questionnaire (EuroQol EQ 5D ).
Work Productivity  and Activity  Impairment (WPAI) Questionnaire.
Functional assessment of chronic illness therap y fatigue (FACIT Fatigue Scale ).
US and Canada ONLY : RAPI D3.
Safety  assessment and AE reporting.
Asses s safet y events for adjudication by [CONTACT_167176].
Concomitant Medication Review .
Dispense investigational products as identified b y the drug dispensing sy stem.   
Dispense dosing diary  to subject and instruct subject on proper use of the diary .
Schedule the subject to return for Visit 2. 

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, 04 Dec 2017
Page 486.2.3. Visit 2 (Week 6 ; Day 42 ) 
There is a ±[ADDRESS_194358] 6 hours prior 
to the visit.   Procedures to be performed at Visit 2 include:
Assessment of new ph ysical findings (weight, vital signs, 
skin examination including 
careful examination for melanom a and nonmelanoma skin cancer , lungs, heart, lower 
extremities for peripheral edema, abdomen and l ymph nodes) .Laboratory  testing 
including blood chemistry , hematology , lipid profile (fasting) .
Biospecimen collection for banking.
Pregnancy  testing must be completed for all women of childbearing potential: all 
subjects must test negative; confirmation and documentation of the use of two highly  
effective methods of contraception b y subjects of childbearing potential or their 
partners must be done. For contra ception an d reproductive status details to be applied 
inBelgium, Czech Republic, German y, Hungary , Italy, Poland, Spain, and the United 
Kingdom see Appendix 7.
Safety  Assessment and AE Reporting. 
Assess safet y events for adju
dication by  [CONTACT_167177]/ review 
committee and collect biopsies of potential malignancy  events for central laboratory  
pathologist over read and report to [COMPANY_007] Study  Team or designee.
Concomitant Medication Review.
Review dosing diary  with the subject.
Schedule t he subject to return for Visit 3 . 
6.2.4.
Visit 3 (Week 12; Day 84)
There is a ±10 day window for this visit.  Procedures to be performed at Visit 3 include:
Assessment of new ph ysical findings (weight, vital signs, skin examination includ ing 
careful examination for melanoma and nonmelanoma skin cancer , lungs, heart, lower 
extremities for peripheral edema, abdomen and l ymph nodes) .
Laboratory  testing including blood chemistry , hematology , CRP, ESR.
Pregnancy  testing must be completed for all women of childbearing potential: all 
subjects must test negative; confirmation and documentation of the use of two highly  
effect ive methods of contraception b ysubjects of 
childbearing potential or their 
partners must be done. For contraception an d repr oductive status details to be applied 
inBelgium, Czech Republic, German y, Hungary , Italy, Poland, Spain, and the United 
Kingdom see Appendix 7.

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, 04 Dec 2017
Page 4928 tender /painful and swollen joint counts .
Completion of the following assessmen ts:
Subject assessment of arthritis pain.
Subject global assessment of arthritis.
Physician global assessment of arthritis.
HAQ DI.
SF36(Version 2, Acute).
EuroQol EQ 5D.
WPAI Questionnaire.
FACI T-Fatigue Scale.
US and Canada ONLY :RAPI D3.
Safety Assessm ent and AE Reporting.
Assess safet y events for adjudication by [CONTACT_167177] /review 
committee and collect biopsies of potential malignancy  events for central laboratory  
pathologist over read and report to [COMPANY_007] Study  Team or designee.
Conc omitant Medication Review.
Return unused investigational products.
Review dosing diary  with the subject.
Dispense investigational products as identified b y the drug dispensing sy stem. 
Schedule the subject to return for Visit 4(Randomization).
6.2.5. Visit 4 (Randomization; Week 24 ; Day 168)
There is a ±[ADDRESS_194359] 6 hours 
prior to the visit .  Procedures to be performed at Visit 4 include:
Assessment of new ph ysical findings (weight, vital signs, skin 
examination including 
careful examination for melanoma and nonmelanoma skin cancer , lungs, heart, lower 
extremities for peripheral edema, abdomen and l ymph nodes ).

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, 04 Dec 2017
Page 50Laboratory  testing including blood chemistry , hematology , CRP, ESR, lipid profile 
(fasting).
Biospecimen collection for banking.
Pregnancy  testing must be completed for all women of childbearing potential: all 
subjects must test negative; confirmation and documentation of the use of two highly  
effective methods of contraception b y subjects of chi ldbearing potential or their 
partners must be done. For contraception an d reproductive status details to be applied 
inBelgium, Czech Republic, German y, Hungary , Italy, Poland, Spain, and the United 
Kingdom see Appendix 7.
28
tender /painful and swollen joint counts.
Completion of the following assessments:
Subject assessment of arthritis pain.
Subject global assessment of arthritis.
Physician global assessment of arthritis.
HAQ DI.
SF 36 (Version 2, Acute).
EuroQol EQ 5D.
WPAI Questionnaire.
FACI T -Fatigue Scale.
US and Canada ONLY : RAPI D3.
Review dosing diary  with the subject.
Safety  Assessment and AE Reporting.
Assess safet y events for adjudication by [CONTACT_167178].
Concomitant Medication Review.
Return unused investigational products.

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, 04 Dec 2017
Page 51Confirm the subject is eligible for randomization ( achieve LDA as ass essed by  
[CONTACT_82274]).
Randomize eligible subjects and dispense investigational product sas identified by  [CONTACT_101148]/drug dispensing sy stem. 
Schedule the subject to return for Visit 5.
QuantiFERON GoldIn-Tube Test will be performed for all subjects (th
ose who 
meet LDA and those who do not meet L DAat week 24) in Belgium, Czech Republic, 
German y, Hungary , Italy, Poland, Spain, and the [LOCATION_008].  For all other 
countries the test will ONLY be performed for subjects who do not achieve LDA at 
Week 24 and are therefore not randomized . 
6.2.6.
Visit 5 (Week 36; Day 252)
There is a ±10 daywindow for this visit.  Procedures to be performed at Visit 5 include:
All Visit 3 assessments (refer to Section 6.2.4).
Schedule the subject to return for Visit 6(End of Study  Visit).
6.2.7.
Visit 6 (End of Study Visit; Week 48; Day 336/Early Withdrawal Visit )
Subjects who d idnot achieve LDA at Week 24 and were therefore not randomized do not 
require a separate EOS visi texcept for QuantiFERON GoldIn-Tube Test
.
There is a ±[ADDRESS_194360] for 6 hours prior to the 
visit.   Procedures to be performed at Visit 6 include:
Complete Phy sical Examination: height, weight, vital sig ns, general appearance, skin 
(presence of rash or suspi[INVESTIGATOR_148352]), HEENT (head, ey es, ears, nose and throat), 
lungs (auscultation), heart (auscultation for presence of murmurs, gallops, rubs), 
lower extremities (peripheral edema), abdominal (palpation and auscultation), 
neurologic (mental status, station, gait, reflexes, motor and sensory  function, 
coordination) and l ymph nodes.
Laboratory  testing including blood chemistry , hematology , CRP, lipid profile 
(fasting), ESR. 
12-lead electrocardiogram.
Biosp ecimen collection for banking.
Pregnancy  testing must be completed for all women of childbearing potential: all 
subjects must test negative; confirmation and documentation of the use of [ADDRESS_194361] be done. For contraception an d reproductive status details to be applied 
inBelgium, Czech Republic, German y, Hungary , Italy, Poland, Spain, and the United 
Kingdom see Appendix 7.
28tender / painful and swollen joint counts.
Completion of the following assessments:
Subject assessment of arthritis pain.
Subject global assessment of arthritis.
Physician global assessment of arthritis.
HAQ DI.
SF 36 (Version 2, Acute).
EuroQol EQ 5D.
WPAI Questio
nnaire.
FACI T Fatigue Scale.
US and Canada ONLY : RAPI D3.
Safety  Assessment and AE reporting. 
Assess safet y events for adjudication by [CONTACT_167179].
Concomitant Medication Review.
Review of dosing diary  with the subject (the diary  will be returned at this visit).
Return unused investigational products.
6.2.8. Telephone Follow -up (At least [ADDRESS_194362] dose of study drugs)
This visit should occur at least [ADDRESS_194363] dose of study  drugs
.  If it is not combined with the End of Study visit, this visit ca n be 
performed over the phone .  There is a +14 day window for the telephone follow - up.
AE assessment.
Pregnancy  status.

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, [ADDRESS_194364]’s medical record.  In an y circumstance, every  effort 
should be made to document subject outcome, if possible.  T he investigator should inquire 
about the reason for withdrawal, request that the subject return all unused investigational 
product(s), request that the subject return for a final visit, if applicable, and follow up with 
the subject regarding an y unresolved adverse e vents ( AEs).
If a subject completel y withdraws from the stud y, and also withdraws consent for disclosure 
of future information, no further evaluations should be performed, and no additional data 
should be collected.  The sponsor may  retain and co ntinue to use an y data collected before 
such withdrawal of consent.
If a subject has discontinued investigational product for greater than [ADDRESS_194365] will be discontinue dfrom the stud y.
Subjects who experience a single epi[INVESTIGATOR_167142] y time during the study  
(including the open -label run -in and double- blind phase) thatcould not be controlled by  
[CONTACT_167180] .
7.ASSESSMENTS
Every  effort should be made to ensure that the protocol -required tests and procedures are 
completed as described. However ,it is anticipated that from time to time there may  be 
circumstances, outside of the control of the inv estigator that may  make it unfeasible to 
perform the test. In these cases the investiga tor is to take all steps necessar y to ensure the 
safet y and well -being of the subject. When a protocol -required test cannot be performed ,the 
investigator is to document the reason for this and any corrective and preventive actions that 
heor she has taken to ensure that normal processes are adhered to as soon as possible. The 
study  team is to be informed of these incidents in a timely  fashion.
7.1. Physical Examination
A complete physical examination will be performed at the Screening Visit, Baseline 
Visit(Visit 1) and End of S tudy Visit (Visit 6) .  The following parameters and body  systems 
will be examined and any  abnormalities described: height (not required for Baseline 
Visit/Visit1) , weight, vital signs, general appearance, skin (presence of rash, skin le sions with 
malignant features), HEENT (head, ey es, ears, nose and throat), lungs (auscultation), heart 
(auscultation for presence of murmurs, gallops, rubs), lower extremities (peripheral edema), 
abdominal (palpation and auscultation), neurologic (mental s tatus, station, gait, reflexes, 
motor and sensory  function, coordination) and l ymph nodes. 

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, 04 Dec 2017
Page 547.2.Assessment of New Physical Findings 
At all other visits (Visits 2-5) , an abbreviated ph ysical examination will be performed 
assessing the following: weight, vital signs, skin examination including careful ex amination 
for melanoma and non- melanoma skin cancer , lungs, heart, lower extremities for peripheral 
edema, abdomen and l ymph nodes. Any clinically  significant changes from the last complete 
physical examination should be recorded as AEs; ongoing AEs should be updated, as 
appropriate. 
7.3. Chest Radiograph
A chest radiograph or chest CT scan will be obtained at the Screening Visit in all subjects, 
unless it has been taken and documented within the [ADDRESS_194366] be negative for active 
tuberculosis infection.
Screening for latent and/or active TB will be conducted using the QuantiFERON-TB Gold 
In-Tube test.  All subjects with positive results must have a chest radiograph performed and 
the radiograph must be negative for active tuberculosis infection.  Subjects identified as 
having latent TB should be treated appropriatel y (see Section [IP_ADDRESS]).
Chest computed tomography  (CT) scans will not be performed as part of the study  
procedures.  However, if a chest CT scan has been performed for other reasons within the 
3months prior to a scheduled chest radiograph
,subjects do not need a new chest radiograph, 
but rather, the results of the chest CT scan may  be used to confirm the absence of active 
tuberculosis infection. 
7.4.Electrocardiogram
A 12 -lead electrocardiogram (ECG) will be obtained on all subjects at the Screening V isit 
and at the End of Study visit.  All ECGs should be performed after the subject has rested 
quietly  for at least [ADDRESS_194367]’s s ource 
documentation.  Subjects with a screening 12 -lead electrocardiogram that demonstrates 
clinically  significant abnormalities requiring urgent treatment (eg, acute my ocardial 
infarction, serious tach y-or brad yarrhythmias) or that is indicative of serio us underly ing 
heart disease (eg, cardiomy opath y, major congenital heart disease, low voltage in all leads)
should not be enrolled in the study .
End of Study  ECGs will be compared to the Screening ECG and any  clinically  significant 
changes will be recorded as adverse events, and evaluated further, as clinically  warranted.
7.5.Assessments of Disease Activity
Individual components for the following indicators of disease activity  will be collected 
throughout the study  as described in Table 3below .

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, 04 Dec 2017
Page 55Table 3. Disease Activity Indicators
Indicator Definition/Calculation
DAS28 -4(CRP) 0.56*√(TJC28) + 0.28*√(SJC28) + 0.36*ln(CRP in mg/l +1) + 
0.014*PtGA in mm+ 0.96
DAS28 -4(ESR) 0.56*√(TJC28) + 0.28*√(SJC28) + 0.70*In(ESR in mm/ hour) + 
0.014*PtGA in mm
Simplified Disease 
Activity Index (SDAI)(28TJC) + (28SJC) + [PhyGA in cm] + [PtGA in cm] + [CRP in 
mg/dL]
Clinical Disease Activity 
Index (CDAI)(28TJC) + (28SJC) + [PhyGA in cm] + [PtGA in cm]
American College of 
Rheumatology (ACR) 
Response RatesThe ACR’s definition for calculating a 20% improvement in 
RA(ACR20) is as follows: a 20 % improvement in tender and 
swollen joint counts and 20% improvement in 3 of the 
5remaining ACR -core set measures: subject and physician global 
assessments, pain, disability, and an acute -phase reactant (eg, 
CRP).  Similarly, ACR50 and 70 are calculated w ith the 
respective percent improvements.
ACR/EULAR 
Boolean -based 
definition of remissionAt any time point, a subject must satisfy all of the following: 
tender joint count 1, swollen joint count 1, CRP 1mg/dL, 
subject ’s global assessment of health 1on a 0 -10scale
TJC =tender joint count; SJC = sw ollen joint count; CRP = C -reactive protein in mg/L; ESR = 
erythrocyte sedimentation rate in mm/first hour, PtGA = subject ’s global assessment of health; PhyGA 
= physician’s global assessment of health
7.6. J oint Counts
7.6.1. Tender/Painful Joint Count (28 Joint Count)
Twenty -eight (28) joints will be assessed by  a blinded joint assessor to determine the number 
of joints that are considered tender or painful.  The response to pressure/motion on each joint 
will be assessed using the following scale: Present/Absent/Not Done/Not Applicable (to be 
used for artificial joints).
The 28 joints to be assessed are the shoulders, elbows, wrists, metacarpophalangeal (MCP) 
joints, proximal interphalangeal (PIP) joints, and knees.  Artificial joints will not be assessed.
7.6.2.
Swollen Joint Count (28 Joint Count)
The blinded joint assessor will also assess these joints for swelling using the following scale: 
Present/Absent/Not Done/Not Applicable (to be used for artificial joints).
The 2 8
swollen joint count includes the following joints: shoulders, elbows, wrists, 
metacarpophalangeal joints (MCP), proximal interphalangeal joints (PI P), and knees.  
Artificial joints will not be assessed.

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, [ADDRESS_194368] Assessment of Arthritis Pain
Subjects will assess the severit y of their arthritis pain using a 100 mm visual analog scale 
(VAS) by [CONTACT_1299] a mark on the scale between 0 (no pain) and 100 (most severe pain), which 
corresponds to the magnitude of their pain.
7.8.Subject Global Assessment of Arthritis
Subjects will answer the following question, “Considering all the way s your arthritis affects 
you, how are you feeling today ?”  The subject’s response will be recorded using a [ADDRESS_194369]’s overall arthritis appears at the time of the visit.   
This is an evaluation based on the subject’s disease signs, functional capacity  and ph ysical 
examination, and should be independent of the Subject ’s Global Assessment of Arthritis.  
The Investigator’s response will be recorded using a 100 mm VAS.
7.10. Health Assessment Questionnaire –
Disability Index (HAQ- DI)
The HAQ -DI12assesses the degree of difficulty a subject has experienced during the past 
week in 8 domains of daily  living activities: dressing and grooming, arising, eating, walking, 
hygiene, reach, grip, and other activities.  Each activity  category  consists of 2 -3items.  For 
each question in the questionnaire, the level of difficulty is scored from 0 to3with 
0representing “no difficulty ,” 1as “some difficulty ,” 2as “much difficulty,” and 3as 
“unable to do”.  An y activity  that requires assistance from another individual or requires the 
use of an assistive device adjusts to a minimum sco re of 2to represent a more limited 
functional status.  The form should then be checked by  [CONTACT_167181].
7.11. SF-
36Health Survey (Version 2, Acute)
The SF -36 (v.2, Acute)13is a 36 -item generic he alth status measure.  It measures 8general 
health domains: phy sical functioning, role phy sical, bodily  pain, general health, vitality , 
social functioning, role emotional and mental health.  These domains can also be summarized 
as phy sical and mental compo nent scores.  The form should be checked for completeness b y 
the site staff. 
7.12. EuroQol EQ -5D Health State Profile 
The EuroQol EQ -5D Health State Profile14is a copyrighted, subject completed instrument 
designed to assess impact on health- related quality  of life in five domains: mobility , 
self-care, usual activities, pain/discomfort, and anxiety /depression.  Additionally , scores from 
the five domains may  be used to calculate a single index value, also known as a utility  score.  
The validity  and reliability  of the EuroQol EQ -5D has been established in a number of 
disease states, including rheumatoid arthritis. The form should then be checked by
 [CONTACT_167182]. 

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, 04 Dec 2017
Page 577.13. Work Productivity and Activity Impairment (WPAI) Questionnaire
The Work Productivity  & Activit y Impairment Questionnaire (WPAI): Rheumatoid Arthritis 
is a 6- item questionnaire that is specific for rheumatoid arthritis and y ields four ty pes of 
scores: absenteeism, presenteesism (impairment at work /reduced job effectiveness), work 
productivity  loss and activity  impairment .15WPAI outcomes are expressed as impairment 
percentages with higher numbers indicating greater impairment and less productivity .
7.14. Func tional Assessment of Chronic Illness Therapy (FACIT) -Fatigue Scale 
The FACI T –Fatigue Scale is a subject completed questionnaire16consisting of [ADDRESS_194370] status (less fatigue).  This questionnaire should be completed b y 
the subject prior to an y procedures being performed at the visit, if possible.  The form should 
then be checked b y site staff 
for completeness. 
7.15. Routine Assessment of Patient Index Data 3 (RAPID3)
RAPI D3is a pooled index of the 3 patient -reported American College of Rheumatology  
rheumatoid arthritis (RA) Core Data Set measures: function, pain, and patient global estimate 
of stat us.  Each of the 3 individual measures is scored 0 to 10, for a total of 30.  Disease 
severit y ma y be classified on the basis of RAPID3 scores: >12 = high; 6.1-12 = moderate; 
3.1-6 = low; < or =3 = remission.17
7.16.
C-reactive Protein (CRP)
The CRP will be collected at the time points identified in the Schedule of Activity and 
analyzed by a central laboratory .  It will be used in the calculation of several efficacy  
parameters.   After randomiza tion, the I nvestigator and other site personnel participating in 
the study  and [COMPANY_007] study  personnel will be kept blinded of the results of this test.
7.17.
Erythrocyte Sedimentation Rate (ESR) 
The ESR will be analy zed by  a local laboratory  using the Westergre n method.  The local 
laboratory  will report results to the central laboratory .  After randomization, the i nvestigator 
and other site personnel participating in the study  and [COMPANY_007] study  personnel will be kept 
blinded of the results of this test.
7.18. Clinical Laboratory Tests
Blood and urine samples will be collected at the time points identified in the Schedule Of 
Activities.  Unscheduled clinical laboratory  tests may  be obtained at any  time during the 
study  to assess an y perceived saf ety concerns.

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, 04 Dec 2017
Page 58Table 4. Clinical Laboratory Tests
Tests Comments
Chemistry:
Urea nitrogen, creatinine, glucose, calcium, 
sodium, potassium, bicarbonate, chloride, total 
protein, total bilirubin, direct bilirubin, indirect 
bilirubi n, alanine aminotransferase (ALT), 
aspartate aminotransferase (AST), alkaline 
phosphatase, gamma -glutamyl transferase (GGT), 
albumin, creatine kinase (CK)Creatinine clearance is calculated by [CONTACT_167183] -Gault Formula at Screening Visit
(Appendix 4)
See Section 7.[ADDRESS_194371] elevated 3X ULN
Hematology:
Hemoglobin, Hematocrit, RBC, RBC morphology, 
WBC, Neutrophils (%, abs), Lymphocytes (%, 
abs), Monocytes (%, abs), Eosinophils (%, abs), 
Basophils (%, abs), PlateletsSeeSection 7.[ADDRESS_194372] -menopausal status , if 
applicable
HIV Serology
Hepatitis B Surface antigen (HBsAg)
Hepatitis B Core Antibody (HBcAb)
Hepatitis B Surfac e Antibody (HBsAb)Subjects with a positive hepatitis B surface 
antigen (HBsAg) test will be excluded from 
the study.
Subjects with HBsAg negative testing but 
who test positive for hepatitis B core antibody 
(HBcAb) must have further testing for 
hepatitis B surface antibody (HBsAb).  If 
HBsAb is negative, the subject will be 
excluded from the study.
Hepatitis C virus antibody (HCV Ab)
Hepatitis C RNA (HCV RNA)Subjects with positive HCV Ab tests will be 
reflex tested for hepatitis C virus ribonucleic 
acid (HCV RNA).  Only subjects with 
negative HCV Ab or HCV RNA will be 
allowed to enroll in the study.
Lipi[INVESTIGATOR_805]:
Triglycerides, Total Cholesterol, HDL (direct), 
LDL (Friedwald)Subjects should be fasting for at least [ADDRESS_194373] 25mIU/mL 
and must be performed by a certified 
laboratory. (See Section 7.19)
May be repeated if pregnancy is suspected or 
at the request of the IRB/EC or local 
regulations.
QuantiFERON TB Gold®™ in Tube Test See Section s5.8.1.1 and 7.3for further details 
on management of positive tests.
Urinalysis:
Specific Gravity, pH, Protein, Glucose
Ketones, Blood, Leukocyte Esterase
Tests to include when repeat AST and/or ALT are 
required:
Albumin
Creatine kinase (CK)
Total bilirubin
Direct bilirubin
Indirect bilirubin
GGT
PT/INR
Alkaline phosphataseSee Section 8.7.2 for further details on 
management of elevations. 
ALT = alanine aminotransferase (SGPT); AST = aspartate aminostransferase (SGOT); HDL = high density 
lipoprotein; HIV = human immunodeficiency virus; LDL = low density lipoprotein; SGOT = serum 
glutamic- oxaloacetic transaminase (AST); SGPT = serum glutamic pyruvate transaminase (ALT); TB = 
tuberculosis; X ULN = times the upper limit of normal; 
Itis recommended that for potential herpes zoster adverse even ts a laboratory diagnosis of varicella 
zoster virus infection be confirmed and that the virus be characterized.  (Specimens should be 
obtained from vesicular fluid, maculopapular lesions, or crusts from lesions).   Details of the test, 
method and laboratory details will be provided in a separate manual.
7.19. Pregnancy Testing
For female subjects of childbearing potential, [ADDRESS_194374].  Pregnancy  tests will also be done whenever 
1menstrual cy cle is missed during the active treatment period (or when potential pregnancy  
is otherwise suspected), and repeated at all study  visits (from screening visit to the end of 

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, 04 Dec 2017
Page 60study visit) to confirm that the subject has not become pregnant during the study .  All 
pregnancy  tests used in this study , either urine or serum, must have a sensitivity  of at least 
25mIU/mL and must be performed b y a cert ified laboratory .  In the case of a positive 
confirmed pregnancy , the subject will be withdrawn from administration of investigational 
product and from the study .  Pregnancy  tests may  also be repeated as per request of 
institutional review boards (I RBs)/et hics committees (ECs) or if required by  [CONTACT_13125]. 
7.20. Adjudicated Events 
The [COMPANY_007] Study  Team or designee will provide a listing of specific documents needed to 
support event adjudication by  [CONTACT_167184] 
(seeSection 9.6).  Obtaining and 
submitting the documentation will be the responsibility  of the study  site.  Event 
documentation will vary  with the event requiring adjudication and may  include (but not be 
limited to): ho
spi[INVESTIGATOR_8838], operative reports, clinic notes, ECGs, diagnostic 
tests, pathology  reports, autopsy  reports and death certificate information, as applicable.
7.21. Banked Biospecimens
7.21.1. Markers of Drug Response
Study ing the variation in genetic marker s and other biomarkers may  help to explain some of 
the variability  in response seen with some drugs among different individuals.  This is referred 
to as pharmacogenomic/biomarker research.  Comparing the deoxy ribonucleic acid (DNA), 
ribonucleic acid (RNA), protein, and metabolite variation patterns of subjects who respond 
well and those who respond poorly  to treatment may  help to better define the most 
appropriate group of subjects in which to target a given treatment.  Collecting biospecimens 
for explorato ry pharmacogenomic/biomarker analy ses and retaining them in the [COMPANY_007] 
BioBank makes it possible to better understand the drug’s mechanism of action and to seek 
explanations for differences in, for example, exposure, efficacy , tolerability , or safet y not 
anticipated prior to the beginning of the study .  Providing these biospecimens is a required 
study  activit y for stud y sites and subjects, unless prohibited as such b y local regulations or 
ethics committee decision. 
To protect subjects’ confidentiality , the banked biospecimens and data generated from them 
will be coded with the subject’s study  identification (ID) number.  Samples will be kept in a 
facility  accessible only  by [CONTACT_167185][INVESTIGATOR_007] a badge.  Data will be stored on password -protected 
computer s ystems.  The k ey between the code and the subject’s personal identifiers will be 
held at the study  site; the researchers using the biospecimens and data generated from them 
will not have access to the key  nor an y personally  identify ing information.  Biospecimens 
will be used only  for the purposes described here and in the informed consent 
document/subject information sheet; an y other uses require additional ethical approval.  
Unless a time limitation is required b y local regulations or ethical requirements, 
biospecimens will be stored indefinitely  to allow for future research on the topi[INVESTIGATOR_167143], including research conducted during the lengthy drug development process and also 
postmarketing research.  Subjects can withdraw their consent for the use of their 
biospecimens at an y time by  [CONTACT_7328] a request to the investigator, in which event any  

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, 04 Dec 2017
Page 61remaining biospecimen will be destroy ed; data already  generated from the biospecimens will 
continue to be stored to protect the integrit y of existing analyses.  It is very  unlikely that 
results generated from the biospecimens will have any  clinical, diagnostic, or therapeutic 
implications for the individual study  participants.  Subjects are notified in the informed 
consent document/subject information sheet that their results wi ll not be given to them, 
unless required b y local laws or regulations, in which case results will be returned via the 
investigator.  Results will not be provided to family  members or other phy sicians, nor will 
they be recorded in the subject’s medical reco rd.  There is no intention to contact [CONTACT_167186] .
A 4-mL blood biospecimen Prep D1 (K2edetic acid [ethylenediaminetetraacetic acid] 
[EDTA] whole blood collection optimized for DNA analysis) will be collected at visits 
1(baseline visit) to be retained for potential pharmacogenomic/biomarker analy ses related to 
drug response .  For example, putative safet y biomarkers, drug -metabolizing enzy me genes, 
drug-transport protein genes, or genes thought to be related to the mecha nism of drug action 
may be examined. 
Prep R1 (PAXGene whole blood collection optimized for RNA analysis) : Two 2.5-mL 
blood biospecimen s(2paxgene tubes, 2.5 ml/tube) will be collected at 
visits 1, 2, 4 and 6 , 
respectivel y, for potential pharmacogenomics/
biomarker an alyses related to drug response.
Additional biospecimens to be retained for exploratory  anal yses in this study  include:
Prep B1 (K2EDTA plasma collection optimized for 
biomarker/proteomic/metabonomic anal ysis): a 10 mL blood biospecimen will be 
collected at visits 1, 2, 4, and 6;
Prep B2 (serum collection optimized for biomarker/ proteomics/metabonomic 
analysis): a 10 mL blood biospecimen will be collected at visits 1, 2, 4, and 6. 
The Banked Biospecimens will be collected from all subjects u nless prohibited by  [CONTACT_167187].  Detailed collection, processing, storage and 
shipment instructions are provided in the central laboratory manual. 
Itis possible that the use of these biospecimens may  result in commerci ally viable products.  
Subjects will be advised in the informed consent document/ subject information sheet that 
they will not be compensated in this event.
7.21.2. Additional Research
Unless prohibited by  [CONTACT_167188], subjects wi ll be asked to 
indicate on the consent form whether they will allow the Banked Biospecimens to also be 
used for the following research:
Investigations of the disease under stud y in the clinical study, and related conditions;

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, 04 Dec 2017
Page 62Biospecimens may  be used as controls.  This includes use in case -control studies of 
diseases for which [COMPANY_007] is researching drug therapi[INVESTIGATOR_014]; use in characterizing the 
natural variation among people in genes, RNA, proteins, and metabolites; and use in 
developi[INVESTIGATOR_4587]/biomarkers. 
Subjects need not provide additional biospecimens for the uses described in this section; the 
biospecimen specified in the Markers of Drug Response section will be used.  Subjects may  
still participate in the clinical study  if they  elect not to allow their banked biospecimens to be 
used for the additional purposes described in this section.
7.22. Assessment of Suicidal Ideation and Behavior (SIB)
There are no current medically  significant suicidality  conc erns for tofacitini b or methotrexate 
in this study  or their respective mechanisms of action.  Ongoing and aggregate cumulative 
safet y reviews and pharmacovigilance activities will be conducted; if an y concerns are 
identified that would warrant changes to these assessments, surveillance tools will be 
implemented, as appropriate.
7.23. Triggered Requirements for Monitoring and Discontinuation Criteria
Conditions in which Prompt Retesting is Required
Condition Action
Neutrophil counts <1000 cells/mm3The subject should return to the study site for 
prompt retesting, ideally within 3-5 days.
Platelet counts <100,000 platelets/mm3The subject should return to the study site for 
prompt retesting, ideally within 3-5 days.
Lymphocyte counts <500 lymphocytes/mm3The s ubject should return to the study site for 
prompt retesting, ideally within 3-[ADDRESS_194375] and/or ALT elevation >3 times 
theupper limit of normal (ULN) *The subject should return to the study site for 
prompt retesting, ideally within 3-5 days*.
Any single hemoglobin value <8.0 g/dL or one 
that drops 2g/dL below baseline. The subject should return to the study site for 
prompt retesting, ideally within 3-5 days.
Any serum creatinine increase >50% over the 
average of screening (most recent va lue prior to 
baseline) and baseline values OR an absolute 
increase in serum creatinine >0.5 mg/dL 
(>44.2mol/L) over the average of screening 
(most recent value prior to baseline) and 
baseline valuesThe subject should return to the study site for 
prompt retesting, ideally within 3-5 days.
*The subject must return to the study site for prompt retesting and include the following tests: albumin, 
creatine kinase (CK), total bilirubin, direct and indirect bilirubin, GGT, PT/INR, and alkaline phosphatase. 
Additional investigations include a detailed history, occupational exposure, sexual history, travel history, 
history of contact [CONTACT_4490] a jaundiced subject, surgery, blood transfusion, history of liver or allergic disease, work 
exposure, history of ethanol, rec reational drug and dietary supplement consumption.  Testing for acute 
hepatitis A, B or C infection and biliary tract imaging may be considered.   A subject with a total bilirubin 
value 2
×ULN concurrently may need to return to the investigational site an d be evaluated as soon as 
possible, preferably within 48 hours from awareness of the abnormal results (refer to Section 8.7.2 ).

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, [ADDRESS_194376] or ALT elevations ≥[ADDRESS_194377] with a total bilirubin value ≥2x ULNTreatment with all study  drugs will be 
discontinued and the subject withdrawn from 
this study . 
2sequential AST or ALT elevations ≥3x 
ULN with an elevated INRTreatment with all study  drugs will be 
discontinued and the subject withdrawn from 
this study .
2sequential AST or ALT elevations ≥3x 
ULN accompanied b y symptoms consistent 
with hepatic injuryTreatment with all study  drugs will be 
discontinued and the subject withdrawn from 
this stud y. 
2sequential AST or ALT elevations ≥5x 
ULN, regardless of Total Bilirubin or 
accompan ying symptomsTreatment with all study  drugs will be 
discontinued and the subject withdrawn from 
this study . 
Two sequential hemoglobin values 
<8.0 g/dL  or a decrea se of more than 30% 
from baseline value;Treatment with all study  drugs will be 
discontinued and the subject withdrawn from 
this study .  Follow up to resolution
Two sequential platelet counts 
<75,000 platelets/mm3;Treatment with all study  drugs will be 
discontinued and the subject withdrawn from 
this study .  Follow up to resolution
2sequential neutrophil counts 
<1000 cells/mm3Treatment with all study  drugs will be 
discontinued and the subject withdrawn from 
this study .  Follow up to resolution
Confir med ly mphocy te counts 
<500 lymphocy tes/mm3 by [CONTACT_167189] .  Follow up to resolution
Confirmed increases in serum creatinine 
>50% over the average of screening and 
baseline values and the absolute value of 
serum creatinine is above upper limit of 
normal range.  Treatment with all study  drugs will be 
discontinued and the subject withdrawn from 
this study .  Retesting should occur until the 
serum creatinine is within 10% of the 
pretreatment value.
Serious infections defined as an y infection 
(viral, bacterial, or fungal) requiring 
parenteral antimicrobial therap y or 
hospi[INVESTIGATOR_2476], or meeting 
other criteria that require the infection to be 
classified as a serious adverse event. Treatment with all study  drugs will be 
discontinued and the subject withdrawn from 
this study
Opportunistic infection , including 
tuberculosis, judged significant by  
[CONTACT_167190] (NMSC) and cervical 
carcinoma in situTreatment with all study drugs will be 
discontinued and the subject withdrawn from this 
study

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, [ADDRESS_194378] withdrawn from this 
study (see Appendix 6for details) .
Anaphylactic or other serious allergic reaction Immediately discontinue study drug and institute 
appropriate therapy.  
Symptoms suggestive of a lupus -like syndro me Discontinue study drug and institute appropriate 
therapy
Other Triggered Requirements for Monitoring
Condition Action
Increase lipid parameters (total cholesterol, 
LDL cholesterol, HDL cholesterol, 
triglycerides)Monitor and treat according to local guidance (eg, 
diet and behavior modification, statin therapy)
Surgery Interrupt study drug 1 week prior to a scheduled 
surgical procedure and may resume when 
operative site is sufficiently healed and risk of 
infection is minimal.
(Study drug administratio n can be resumed only if 
the off- drug period is 14consecutive days.) 
Use of potent CYP3A4 and 
CYP2C19 Inhibitors and CYP3A4 InducersTreatment with potent CYP3A4 inhibitors or with 
medications that are both a moderate 
CYP3A4 inhibitor and potent inhibi tor of 
CYP2C19 require that tofacitinib is interrupted 
during treatment.  Treatment with a potent 
CYP3A4 does not require tofacitinib 
discontinuation but should be noted as a protocol 
deviation.  See Appendix 3for a list of 
CYP3A4 and CYP2C19 Inhibitors and 
CYP3A4 Inducers.
ALT = alanine aminotransferase; AST = aspartate aminotransferase; g/dL = grams per deciliter; GGT = 
gamma -glutamyl transpeptidase, HDL= = high density lipoprotein; LDL= low density lipoprotein ;PT/INR = 
Prothrombin Time International Normalized Ratio; mm = millimeter; x ULN = times the upper limit of normal
8.ADVERSE EVENT REPORT ING
8.1.Adverse Events
All observed or volunteered AEs regardless of treatment group or suspected causal 
relationship to the investigational product(s) will be reported as described in the following 
sections. 

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, [ADDRESS_194379] pursue and obtain information adequate both to determine 
the outcome of the AEand to assess whether it meets the criteria for classification as a 
serious adverse event ( SAE ) requiring immediate notification to [COMPANY_007] or its designated 
representative.  For all AEs, sufficient information should be obtained by  [CONTACT_8889].  The investigator is required to asse ss causality .  
Follow -up by  [CONTACT_47610] a level acceptable to the investigator, and [COMPANY_007] concurs with that assessment.
As part of ongoing safet y reviews conducted b y the sponsor , any non -serious AEthat is 
determined b y the sponsor to be serious will be reported by  [CONTACT_941] s ponsor as a n SAE .  To assist 
in the determination of case seriousness ,further information may  be requested from the 
investigator to provide clarity  and understan ding of the event in the context of the clinical 
study .
8.2.Reporting Period
For 
SAE s, the active reporting period to [COMPANY_007] or its designated representative begins from 
the time that the subject provides informed consent, which is obtained prior to the subjec t’s 
participation in the study , ie, prior to undergoing any  study -related procedure and/or 
receiving investigational product, through a nd including [ADDRESS_194380] after the active 
reporting period has ended should be reported to the 
sponsor if the investigator becomes 
aware of them; at a minimum, all SAEs that the investigator believes have at least a 
reasonable possibility  of being related to investigational produc tare to be reported to the 
sponsor.
AEs (serious and non -serious) should be recorded on the c ase report f orm ( CRF )from the 
time the subject has taken at least 1dose of investigational product through the subject ’slast 
visit.
8.3.Definition of an Adverse E vent
An AEis an y untoward medical occurrence in a clinical investigation subject administered a 
product or medical device; the event need not necessarily  have a causal relationship with the 
treatment or usage.  Examples of AEs include but are not limited to: 
Abnormal test findings;
Clinically  significant symptoms and signs;
Changes in physical examination findings;
Hypersensitivity ;
Progression/worsening of underl ying disease ;
Drug abuse;

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, 04 Dec 2017
Page 66Drug dependency .
Additionally , they  may  include the signs or s ymptoms resulting from:
Drug overdose;
Drug withdrawal;
Drug misuse; 
Drug interactions;
Extravasation;
Exposure during pregnancy (EDP) ;
Exposure via breastfeeding ;
Medication error ;
Occupational e xposure.
8.4.Medication Errors
Medication errors may  result, in this study , from the administration or consumption of the 
wrong product , by [CONTACT_1148], at the wrong time, or at the wrong dosage strength.  
Such medication errors occurring to a stud y participant are to be captured on the medication 
error CRF ,which is a specific version of the AE page ,and on the SAE form when 
appropriate.  In the event of medication dosing error, the sponsor should be notified 
immediately .
Medication errors are reportable irrespective of the presence of an associated AE/SAE, 
including:
Medication errors involving subject exposure to the investigational product;
Potential medication errors or uses outside of what is foreseen in the protocol that do 
or do not involve the participating subject.
Whether or not the medication error is accom panied by  [CONTACT_1149], as determined by  [CONTACT_1275], the medication error iscaptured on the medication error version of the AE page 
and, if applicable, an y associated AE(s) are captured on an AE CRF page.
For the purpose of this study, medication errors will be reported as protocol deviations if the 
subject reported taking 2 -fold or more of their prescribed dose for one or more day s or were 
identified as consuming more than 120% of their prescribed dose over the visit interval. 
Examples of overdose for each investigational product are listed in Sections 8.4.1 and8.4.2.

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, 04 Dec 2017
Page 678.4.1. Tofacitinib Overdose
All overdoses are medication errors.  Ther e is no experience with tofacitinib overdose .  
Pharmacokinetic data up to and including a single dose of 100 mg in healthy  volunteers 
indicate that more than 95% of the administered dose is expected to be eliminated within 
24hours.  There is no specific a ntidote for overdose with tofacitinib.  I n case of an overdose, 
it is recommended that the subject be monitored for signs and symptoms of adverse 
reactions.  Subjects who develop adverse reactions should receive appropriate treatment.
Overdoses of tofaciti
nib are defined b y doses and duration of dosing not administered in the 
tofacitinib development program.  The following doses and duration of dosing have been 
administered in tofacitinib rheumatoid arthritis clinical trials without evidence of 
dose-limitin g symptoms and are not considered overdoses:
≤100 mg tofacitinib daily for up to 2 weeks.
≤60 mg tofacitinib daily  for up to 6 weeks.
≤30 mg tofacitinib daily  for up to 6 months.
Please note, that concomitant treatment with a prohibited potent CYP3A4 inhibitor 
(Appendix 3) is assumed to result in a doubling of exposure.  For further details, please refer 
to the tofacitinib I nvestigator Brochure.
8.4.2. Methotrexate 
Overdose
Leucovorin is indicated to diminish the toxicity  and counteract the effect of methotrexate 
overdose.  Leuco vorin administration should begin as promptly  as possible.   As the time 
interval between MTX administration and leucovorin initiation increases, the effectiveness of 
leucovorin in counteracting toxicity  decreases.
  Monitoring of the serum MTX concentration
is essential in determining the optimal dose and duration of treatment with leucovorin.
In cases of massive overdos e, hydration and urinary  alkalinization may  be necessary  to 
prevent the precipi[INVESTIGATOR_167144]/or its metabolites in the renal tubules.
  For further 
details, please refer to the product label for MTX. 
8.5.Serious 
Infections 
A serious infection is an y infection (viral, bacterial, and fungal) that requires hospi[INVESTIGATOR_167145] y or meets other criteria that require 
it to be classified as a serious adverse event.  A subject who experiences a serious infection 
should be discontinued from the study  and the serious adverse event should be listed as the 
reason for discontinuation in the CRF .  Appropr iate laboratory  investigations, including but 
not limited to cultures should be performed to establish the etiology  of any  serious infection.  
All adverse events, including serious adverse events, should be reported as described in 
Section 8.[ADDRESS_194381] finding should be reported as 
an AEare as follows: 
Test result is associated with accompan ying symptoms; and/or
Test result requires additional diagnostic testing or medical/surgical intervention ;
and/or
Test result leads to a change in study  dosing (outside of protocol -stipulated dose 
adjustments) or discontinuation from the study , signific ant additional concomitant 
drug treatment, or other therap y;and/or
Test result is considered to b e an AEby [CONTACT_4687].
Merel y repeating an abnormal test, in the absence of an y of the above conditions, does not 
constitute an AE.  An y abno rmal test result that is determined to be an error does not require 
reporting as an AE.
Clinically  significant laboratory  findings at the final assessment should be followed to 
resolution or until determined by [CONTACT_74089].  Repeat te sts may be 
indicated to establish this. 
8.7.Serious Adverse Events
Aserious adverse event is any  untoward medical occurrence at any  dose that:
Results in death;
Is life -threatening (immediate risk of death);
Requires inpatient hospi[INVESTIGATOR_1081];
Results in persistent or significant disability /incapacity (substantial disruption of the 
ability  to conduct normal life functions);
Results in congenital anomaly/birth defect.
Lack of efficacy  should be reported as an AE when it is associated with a nSAE .
Medical and scientific judgment isexercised in determining whether an event is an important 
medical event.  An important medical event may  not be immediately  life-threatening and/or 
result in death or hospi[INVESTIGATOR_059].  However, if it is determined that the event may  jeopardize 
the subject or may  require intervention to prevent one of the other AEoutcomes, the 
important medical event should be reported as serious.

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, 04 Dec 2017
Page 69Examples of such events are intensive treatment in an emergenc y room or at home for 
allergic bronchospasm; blood dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_059]; 
ordevelopment of drug dependency  or drug abuse.
8.7.1. Protocol -Specified Serious Adverse Events 
There are no protoco l
-specified SAEs in this stu dy. All SAEs will be reported by  [CONTACT_4688], and will be handled as SAEs in the safet y 
database (see thesection onSerious Adverse Event Reporting Requirements).
8.7.2. Potential Cases of Drug
-Induced Liver Injury 
Abnormal values in aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) 
levels concurrent with abnormal elevations in total bilirubin level that meet the criteria 
outlined below in the absence of other causes of liver injury  are considered potential cases of 
drug-induced liver injury (potential Hy ’s law cases) and should alway s be considered 
important medical events. 
The threshold of laboratory  abnormalities for a potential case of drug- induced liver injury  
depends on the subject’s individual baseline values and underl ying conditions.   Subjects who 
present with the following laboratory  abnormalities should be evaluated further to 
definitively  determine the etiology  of the abnormal laboratory
 values:
Subjects with AST o r ALT and total bilirubin baseline values within the normal range 
who subsequently  present with AST or AL T values 3times the upper limit of 
normal (×ULN) concurrent with a total bilirubin value  2 ×ULN with no evidence 
of hemoly sis and an alkaline phos phatase value 2 × ULN or not available;
For subjects with preexisting AL TOR AST OR total bilirubin values above the 
ULN , the following threshold values should be used in the definition mentioned 
above:
For subjects with pre existing AST or AL T baseline va lues above the normal 
range: AST or ALT 
values  2times the baseline values and 3 ×ULN, or 
8 ×ULN (whichever is smaller).
Concurrent with
For subjects with pre existing values of total bilirubin above the normal range: 
Total bilirubin level increased from baseline b y an amount of at least 1 ×ULN or
if the value reaches ≥3×ULN (whichever is smaller).
The subject should return to the investigational site and be evaluated as soon as possible, 
preferabl y within [ADDRESS_194382] bilirubi n, gamma- glutamyl 
transferase, prothrombin time (PT)/ international normalized ratio ( INR), and alkaline 
phosphatase.  A detailed history , including relevant information, such as review of ethanol, 
acetaminophen , recreational drug ,and supplement consumptio
n, family  history , occupational 
exposure, sexual history , travel history , history  of contact [CONTACT_4490] a jaundiced person , surgery , 
blood transfusion, history of liver or allergic disease, and work exposure, should be collected.  
Further testing for acute hepat
itis A, B, or C infection and liver imaging ( eg, biliary  tract) 
may be warranted.   All cases confirmed on repeat testing as meeting the laboratory  criteria 
defined above , with no other cause for liver function test ( LFT
)abnormalities identified at 
the tim e,should be considered potential Hy ’s law cases irrespective of availability of all the 
results of the investigations performed to determine etiology  of the abnor mal L FTs.  Such 
potential Hy ’s law cases should be reported as SAEs.
8.8.Hospi[INVESTIGATOR_47575] y initial admission (even less than 24 hours) in a hospi[INVESTIGATOR_8843].  Admission also 
includes transfer within the hospi[INVESTIGATOR_4591]/intensive care unit (eg, f rom the psy chiatric 
wing to a medical floor, medical floor to a coronary  care unit, or neurological floor to a 
tuberculosis unit).  An emergency  room visit does not necessarily constitute a hospi[INVESTIGATOR_059]; 
however, the event leading to the emergency  room visit should be assessed for medical 
importance.
Hospi[INVESTIGATOR_4592]:
Rehabilitation facilities;
Hospi[INVESTIGATOR_4593];
Respi[INVESTIGATOR_4594] ( eg,caregiver relief);
Skilled nursing facilities;
Nursing homes;
Same -day surgeries (as out subjec t/same -day/ambulatory  procedures).
Hospi[INVESTIGATOR_4595] a precipi[INVESTIGATOR_2505], clinical 
AEis not in itself a nSAE .  Examples include: 
Admission for treatment of a preexisting condition not associated with the 
development of a new AEor with a worsening of the preexisting condition ( eg, for 
work up of persistent pretreatment lab oratory abnormality );
Social admission ( eg, subject has no place to sleep);

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, 04 Dec 2017
Page 71Administrative admission ( eg,for yearly physical exam ination );
Protocol -specified admission during a study  (eg,for a procedure required by  [CONTACT_8896]);
Optional admission not associated with a precipi[INVESTIGATOR_4596] (eg,for elective 
cosmetic surgery );
Hospi[INVESTIGATOR_4597] a medical AE;
Preplanned treatments or surgical procedures .  These should be noted in the baseline 
documentation for the entire protocol and/or for the individual subject ;
Diagnostic and therapeutic noninvasive and invasive procedures, such as surgery , should not 
be rep orted as 
AEs.  However, the medical condition for which the procedure was performed 
should be reported if it meets the definition of an AE.  For example, an acute appendicitis 
that begins during the AEreporting period should be reported as the AE, and the resulting 
appendectomy  should be recorded as treatment of the AE.
8.9.Severity Assessment
If required on the AECRFs , the investigator will use the adjectives M ILD, MODERATE, 
or SEVERE to describe the maximum intensity  of the AE.  For purposes of consistency ,
these intensity  grades are defined as follows:
MILD Does not interfere with subject's usual function.
MODERATE Interferes to some extent with subject's usual function.
SEVERE Interferes significantl y with subject's usual function.
Note the distinctio n between the severit y and the seriousness of an AE.  A severe event is not 
necessarily  an SAE .  For example, a headache may  be severe (interferes significantly  with 
the subject's usual function) but would not be classified as serious unless it met one of the 
criteria for SAE s, listed above.
8.10. Causality Assessment
The investigator’s assessment of causalit y must be provided for all AEs (serious and 
non-serious); the investigator must record the causal relationship in the CRF, as appropriate, 
and report such an assessment in accordance with the SAE reporting requirements if 
applicable.  An investigator’s causality  assessment is the determination of whether there 
exists a reasonable possibility  that the investigational product caused or contributed to an 
AE; gene rally the facts (evidence) or arguments to suggest a causal relationship should be 
provided
.  If the investigator does not know whether or not the investigational product caused 
the event, then the event will be handled as “related to investigational produ ct” for reporting 
purposes, as defined b y the sponsor (see the s ection on Reporting Requirements ).  If the 
investigator's causality assessment is "unknown but not related to investigational product ," 
this should be clearl y documen ted on study  records. 

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, [ADDRESS_194383] this causal relationship in the source documents and CRF, as 
appropriate, and report such an assessment in acco rdance with the SAE reporting 
requirements, if applicable.
8.11. Exposure During Pregnancy
For both unapproved/unlicensed products and for marketed products , an exposure during 
pregnancy  occurs if:
1.A female becomes, or is found to be, pregnant either while rece iving or having been 
exposed (eg , because of treatment or environmental exposure) to the investigational 
product; or the female becomes or is found to be pregnant after discontinuing and/or 
being exposed to the investigational product
;
An example of enviro nmental exposure would be a case involving direct contact [CONTACT_4490] 
a [COMPANY_007] product in a pregnant woman (eg , a nurse reports that she is pregnant and has 
been exposed to chemotherapeutic products).
2. A male has been exposed (eg, because of treatment or environme ntalexposure) to the 
investigational product prior to or around the time of conception and/or is exposed 
during his partner’s pregnancy .
If astudy  subject or study  subject’s partner becomes or is found to be pregnant during the 
study  subject’s treatment with the investigational product, the investigator must submit this 
information to the [COMPANY_007] drug safety unit on an SAE report form and an EDP supplemental 
f
orm, regardless of whether an SAE has occurred.  In addition, the investigator must submit 
inform ation regarding environmental exposure to a [COMPANY_007] product in a pregnant woman ( eg, a 
subject reports that she is pregnant and has been exposed to a cy totoxic product by  [CONTACT_8897][INVESTIGATOR_4598]) using the EDP supplemental f orm.  This must be done irrespecti ve of whether an 
AEhas occurred and within 24 hours of awareness of the exposure. The information 
submitted should include the anticipated date of delivery  (see below for information related 
to termination of pregnancy ).
Follow -up is conducted to obtain general information on the pregnancy  and its outcome for 
all EDP reports with an unknown outcome.  The investigator will follow the pregnancy  until 
completion (or until pregnancy  termination) and notify  [COMPANY_007] of the outcome as a follow-up 
to the initial EDP supplemental f orm.  In the case of a live birth, the structural integrity  of the 
neonate can be assessed at the time of birth.  In the event of a termination, the reason(s) for 
termination should be specified and, if clinicall y possible, the structural integrity  of the 
terminated fetus should be assessed b y gros s visual inspection (unless pre -procedure test 
findings are conclusive for a congenital anomal y and the findings are reported).
If the outcome of the pregnancy  meets the criteria for an SAE (ie, ectopic pregnancy , 
spontaneous abortion, intrauterine fetal demise, neonatal death, or congenital anomal y [in a 
live-born baby, a terminated fetus, an intrauterine fetal demise, or a neonatal death]), the 
investigator should follow the procedures for report ing SAEs.

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, 04 Dec 2017
Page 73Additional information about pregnancy  outcomes that are reported as SAE s follows: 
Spontaneous abortion includes miscarriage and missed abortion ;
Neonatal deaths that occur within [ADDRESS_194384].
Additional information regarding the EDP may be reque sted by  [CONTACT_093].  Further 
follow -
up of birth outcomes will be handled on a case- by-case basis ( eg, follow -up on 
preterm infants to identify developmental delay s).In the case of paternal exposure, the 
investigator will provide the study  subject w ith the Pregnant Partner Release of Information 
Form to deliver to his partner. The i nvestigator must document in the source documents that 
the subject was given the Pregnant Partner Release of Information Form to provide to his 
partner.
8.12. Occupational Exposure
An occupational exposure occurs when ,during the performance of job duties, a person 
(whether a healthcare professional or otherwise) gets in unplanned direct contact [CONTACT_8898], which may  or may  not lead to the occurrence of an AE.
An occupational exposure is reported to the drug safet y unit within 24 hours of the 
investigator’s awareness, using the SAE r eport form, regardless of whether there is an 
associated AE/SAE.  Since the information does not pertain to a subject enrolled in the study , 
the information is not reported on a CRF ; however ,a cop y of the completed SAE report form 
is maintained in the investigator site file.
8.13. Withdrawal Due to Adverse Events (See Also the Section on Subject Withdrawal )
Withdrawal due to AEs should be distinguished from withdrawal due to other causes, 
according to the definition of AEnoted earlier, and recorded on the appropriate AECRF 
page.  A complete list of specific discontinuation criteria for this study  is listed in 
Section 7.23.
When a subject withdraws because of 
anSAE , the SAE must be reported in accordance with 
the reporting requirements defined below.
8.14. Eliciting Adverse Event Information
The investigator is to repor t all directly  observed AEs and all AEs spontaneously  reported b y 
the study  subject. In addition, each study  subject will be questioned about AEs.
8.15. Reporting Requirements
Each AEis to be assessed to determine if it meets the criteria for SAE s.  If a nSAE occurs, 
expedited reporting will follow local and international regulations, as appropriate.

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, [ADDRESS_194385] be 
made immediately , irrespective of the extent of available AEinformation.  This time frame 
also applies to additional new information (follow -up) on previousl y forwarded SAE reports 
as we ll as to the initial and follow -up reporting of 
EDP ,exposure via breastfeeding, and 
occupational exposure cases. 
In the rare event that the investigator does not become aware of the occurrence of a nSAE
immediately  (eg, if an out subject study  subject ini tially  seeks treatment elsewhere), the 
investigator is to report the event within [ADDRESS_194386] awareness of the AE.
For all SAE s, the investigator is obligated to pursue and provide information to [COMPANY_007] in 
accordance with the time frames for reporting specified above.  In addition, an investigator 
may be requested by  [CONTACT_4695] -up information in an 
expedited fashion.  This i nformation collected for SAE sismore deta iled than that captured 
on the AE CRF .  In general, this will include a description of the AEin sufficient detail to 
allow for a complete medical assessment of the case and independent determination of 
possible causality .  Information on other possible ca uses of the event, such as concomitant 
medications, vaccines, and/orillnesses, must be provided.  In the case of a subject death, a 
summary of available autopsy  findings must be submitted as soon as possible to [COMPANY_007] or its 
designated representative. 
8.15.2. Non-serious Adverse Event Reporting Requirements
All AEs will be reported on the AEpage(s) of the CRF.  I t should be noted that the form for 
collection of SAE information is not the same as the AECRF.  Where the same data are 
collected, the forms must be c ompleted in a consistent manner.  For example, the same AE
term should be used on both forms.  AEs should be reported using concise medical 
terminology  on the CRFs as well as on the form for collection of SAE information.
8.15.3. Sponsor ’sReporting Requirements t o Regulatory Authorities
AEreporting, including suspected unexpected serious adverse reactions, will be carried out 
in accordance with applicable local regulations.
9. DATA ANALYSIS/STATIS TICAL METHODS
Methodologies for summary  and statistical analyses of da ta collected in this study  are 
summarized here and further detailed in a Statistical Analysis Plan (SAP), which will be 
maintained by [CONTACT_456].   This document may  modify  the plans outlined in the protocol; 
however, an y major modifications of the primary endpoint definition and/or its analy sis will 
also be reflected in a protocol amendment.

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, 04 Dec 2017
Page 759.1.Sample Size Determination
Based on estimated CDAI -based low disease activity  rate of 40% derived from prior phase 
3studies and factoring in a discontinuation rate of approximatel y 15% during the open label 
run-in phase , approximately [ADDRESS_194387] 232subjects being randomized into the blinded MTX withdrawal phase at W eek 24.   
With a two -sided Ty pe-I error o f 5% and an assumed standard deviation of 1.4 for the 
difference in change from randomization in DAS28-4 (ESR) between the two arms, a sample 
size of approximately  232subjects randomized at Week 24 would provide 90% power to 
declare non -inferiority  of tof acitinib monotherap y relative to tofacitinib plus methotrexate 
with a non- inferiorit y margin of 0.6.
9.2.Descriptive Analysis
Patient and clinical characteristics at baseline and randomization (ie, the end of open- label
phase) will be summarized with the use o f descriptive statistics.   Frequencies and percentages 
will be used to describe categorical variables and mean and standard deviations (or median 
with interquartile range [IQR] and range, where appropriate) will be calculated for 
continuous variables.
Descriptive statistics will also be provided 
for all efficacy  and safet y endpoints at each visit 
in open- label phase or double -blind withdrawal phase as appropriate.  Further details will be 
outlined in the SAP. 
9.3.Efficacy Analysis
9.3.1. Analysis of the Primary Endpo int 
The primary  endpoint of change from randomization in DAS28 -4(ESR) at W eek [ADDRESS_194388] model of repeated measures 
(MMRM) that includes the fixed effects of treatment, visit, treatment -by-visit interaction, 
prior use of a biological DMARD, and baseline DAS28 -4 (ESR) value as a covariate.   
Within -subject variability will be accounted for using a random effect with an unstructured 
covariance matrix.   Change from randomization at any  visit post -randomization will be 
defined as the DAS28 -
4(ESR) value at that visit minus the value at randomization.
The primary  anal ysis will be a non- inferiority test to show that tofacitinib MR 11mg QD 
monotherap y is not less effective (non -inferior) than tofacitini b MR 11mg QD with MTX 
within the margin of non -inferiorit y set at 0.6 (ie, the difference in mean c hange from 
randomization in DAS 28
-4(ESR) between the two arms) . In other words, the change from 
randomization in DAS28 -4(ESR) for the tofacitinib MR 11mg Q D monotherap y arm may  be 
less favorable than that for the tofacitinib MR 11mg QD with continued MTX arm b y no 
more than 0.6. The estimated treatment difference and the associated 95% confidence 
interval (CI) will be presented.  If the upper bound of the 95% two- sided CI  for the difference 
(tofacitinib monotherap y arm minus tofacitinib with MTX arm) in change from 
randomization in DAS 28 -4 (ESR) between the two arms is lower than 0.6, then tofacitinib 
monotherap y will be declared to be non -inferior to the t ofacitinib with continued MTX 
treatment.

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, 04 Dec 2017
Page 76The analysis will be based on the Full Analysis Set (FAS), which is defined as those subjects 
who received at least one dose of tofacitinib plus MTX during the open label period and were randomized and received at least one dose of the randomized investigational drug (tofacitinib MR 11mg QD with placebo for MTX or tofacitinib MR 11mg QD with MTX) during the blinded MTX withdrawal period.
A robustness analysis based on a per-protocol analysis set will be performed.  Sensitivity 
analyses using different methods of handling missing data will also be conducted; further details will be outlined in the SAP.
9.3.2. Analysis of Secondary Endpoints
Binary secondary endpoints will be analyzed using the normal approximation for the 
difference in binomial proportions.
Continuous secondary endpoints will be analyzed using similar methods as the primary 
endpoint, ie, a linear mixed-effect model of repeated measures (MMRM) that includes the fixed effects of treatment, visit, treatment-by-visit interaction, and baseline value as a covariate.  Within-subject variability will be accounted for using a random effect with an unstructured covariance matrix.
The estimated treatment difference and the associated 95% confidence interval (CI) will be 
presented. 
9.4. Analysis of Other Efficacy and Exploratory Endpoints
Analyses for other efficacy endpoints and exploratory endpoints will be discussed and 
detailed in the SAP.
9.5. Safety Analysis
The safety analysis set is defined as those subjects who received at least one dose of 
tofacitinib MR 11mg QD with MTX at entry into the study.  All displays of safety data will be separated by [CONTACT_65464]-label phase and the double-blind phase.
 
 
 
 
CCI
Tofacitinib citrate
A3921192
Final Protocol Amendment 2, 04 Dec 2017
Page 779.7.Data Monitoring Committee
This study  will use an External D ata Monitoring Committee ( EDMC ).
The EDMC will be responsible for ongoing monitoring of the safety  of subjects in the study  
according to the charter.  The recommendations made b y the EDMC to alter the conduct of 
the study  will be forwarded to [COMPANY_007] for final decision.  [COMPANY_007] will forw ard such decisions, 
which may  include summaries of aggregate analy ses of endpoint events and of safet y data 
that are not endpoints, to regulatory  authorities, as appropriate. 
9.8.Safety Event Adjudication/Review Committees 
To help assess specific safety  even ts in this study , external adjudication committees have 
been established to harmonize and standardize selected safet y event assessment.  Members of 
these safet y event adjudication committees will be blinded to treatment assignment in order 
to allow for unb iased assessments. These committees include a Cardiovascular Endpoint 
Adjudication Committee (CV EAC), Malignancy  Adjudication Committee (MAC), 
Opportunistic Infection Review Committee (OI RC), Hepatic Event Review Committee 
(HERC) and Gastrointestinal Per foration Review Committee (GI PRC). Further information 
about these committees can be found in the respective charters, including specific 
descriptions of the scope of their responsibilities and the processes and definitions used to 
review and assess speci fic safet y events. 
In addition to these external committees, an internal committee of medically qualified [COMPANY_007] 
personnel with expertise in the assessment and diagnosis of respi[INVESTIGATOR_167146] (Interstitial L ung Disease Review 
Committee, ILDRC).
Additional safet y event adjudication or review committees may be established to harmonize 
and standardize selected safet y event assessments.  As described above, individual committee 
charters will provide specific descriptions of the scope of responsibilities and the processes 
and definitions used to review and assess specific safet y events.
In addition to the event adjudication or review committees described above, all biopsies of 
potentially  malignant tumors, suspi[INVESTIGATOR_167147] y, or possible extranodal 
lymphoproliferative disorder 
are to be submitted to the central laboratory  for review by  
[CONTACT_167191].   In some instances, additional expert pathology  review of 
submitt ed samples may  be performed.  Description of the scope of review and the processes 
used to obtain and assess biopsies is described in the Histopathology  Review for Potential 
Malignancy  charter.
10.QUALITY CONTROL AND QUALITY ASSURANCE
[COMPANY_007] or its designee will conduct periodic monitoring visits during study  conduct to ensure 
that the protocol and Good Clinical Practices ( GCPs )are being followed.  The monitors may  
review source documents to confirm that the data recorded on CRFs areaccurate.  The 
investigat or and institution will allow [COMPANY_007] monitors /auditors or its agents and appropriate 
regulatory  authorities direct access to source documents to perform this verification.   This 
verification may  also occur after study  completion.

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, [ADDRESS_194389] and/o r after stud y completion, t he study  site may  be subject to review 
by [CONTACT_941] i nstitutional review board (I RB)/ ethics committee (EC), and/or to quality  assurance 
audits performed b y [COMPANY_007], or companies working with or on behalf of [COMPANY_007], and/or to 
inspection by [CONTACT_47615].
The investigator(s) will notify  [COMPANY_007] or its agents immediately  of any  regulatory  inspection 
notification in relation to the study . Furthermore, the investigator will cooperate with [COMPANY_007] 
or its agents to prepare t
he study  site for the inspection and will allow [COMPANY_007] or its agent, 
whenever feasible, to be present during the inspection. The investigator will promptly  
provide copi[INVESTIGATOR_4599].  Before response submission 
to the regulatory  authorities, the investigator will provide [COMPANY_007] or its agents with an 
opportunity  to review and comment on responses to any  such findings.
It is important that the investigator(s) and their relevant personnel are available during the 
monitor ing visits and possible audits or inspections and that sufficient time is devoted to the 
process.
11.DATA HANDLING AND RE CORD KEEPI[INVESTIGATOR_1645]
11.1. Case Report Forms/Electronic Data Record
As used in this protocol, the term CRF should be understood to refer to either a pap er form or 
an electronic data record or both, depending on the data collection method used in this study .
A CRF is required and should be completed for each included subject.  The completed 
original CRFs are the sole propert y of [COMPANY_007] and should not be ma de available in any  form to 
third parties, except for authorized representatives of [COMPANY_007] or appropriate regulatory  
authorities, without written permission from [COMPANY_007].
The investigator has ultimate responsibility  for the collection and reporting of all c linical, 
safet y
,and laboratory  data entered on the CRFs and any  other data collection forms (source 
documents) and ensuring th at they  are accurate, authentic /original, attributable, complete, 
consistent, legible, timely  (contemporaneous), enduring ,and av ailable when required.  The 
CRFs must be signed by  [CONTACT_110292]. Any correcti ons to entries made in the CRFs or source 
documents must be dated, initialed ,and expl ained (if necessary ) and should not obscure the 
original entry . 
In most cases, the source documents are the hospi[INVESTIGATOR_307]'s or the ph ysician's subject chart.  In 
these cases, data collected on the CRFs must match the data in those charts. 
In some cases, the C RF, or part of the CRF, may  also serve as source documents.  In these 
cases, a document should be available at the investigat ivesite as well as at [COMPANY_007] and clearl y 
identify  those data that will be recorded in the CRF, and for which the CRF will stand as the 
source document.

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, [ADDRESS_194390] Retention
To enable evaluations and/or audits from regulatory  authorities or [COMPANY_007], the investigator 
agrees to keep records, including the identity  of all participating subjects (sufficient 
information to link records, eg,CRF s and hospi[INVESTIGATOR_1097]), all original signed informed 
consent documents , copi[INVESTIGATOR_4600], safety  reporting forms, source documents, and 
detailed records of treatment disposition, and adequate documentation of relevant 
correspondence ( eg,letters, meeting minutes, and telephone call reports).  The records should 
be retained b y the investigator according to the ICH guidelines, according to local 
regulations, or as specified in the c linical study agreement (CSA) , whichever is longer.
If the investigator bec omes unable for any  reason to continue to retain study  records for the 
required period ( eg, retirement, relocation), [COMPANY_007] should be prospectivel y notified.  The 
study  records must be transferred to a designee acceptable to [COMPANY_007] , such as another 
investi gator, another institution, or an independent third party  arranged by  [CONTACT_4618]. 
Investigator records must be kept for a minimum of [ADDRESS_194391] obtain [COMPANY_007]'s written permission before disposing of an y records, 
even if retention requirements have been met.
12.ETHICS
12.1. Institutional Review Board/Ethics Committee
It is the responsibility  of the investigator to have prospective approval of the study  protocol, 
protocol amendments, informed consent documents, and other relevant documents, eg,
recruitment advertisements, if applicable, from the I RB/EC.  All correspondence with the 
IRB/EC should be retained in the investigator f ile.  Copi[INVESTIGATOR_1099]/EC approvals should be 
forwarded to [COMPANY_007].
The only  circumstance in which an amendment may  be initiated prior to IRB/EC approval is 
where the change is necessary  to eliminate apparent immediate hazards to the subjects.  In 
that event, the investigator must notify  the IRB/EC and [COMPANY_007] in writing immediately  after 
the implementation.
12.2. Ethical Conduct of the Study
The study  will be conducted in accordance with legal and regulatory  requirements, as well as 
the general principles set forth in the International Ethical Guidelines for Biomedical 
Research Involving Human Subjects (Council for International Organizations of Medical 
Sciences 2002), Guidelines for GCP (ICH 1996), and the Declaration of Helsinki (World 
Medical Association 1996 & 2008). 
In addition , the study  will be conducted in accordance with the protocol, the ICHguideline 
on GCP , and applicable local regulatory  requirements and laws.

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, [ADDRESS_194392]’s numerical c ode to his or her actual identity .  In case of data transfer, [COMPANY_007] will 
maintain high standards of confidentialit y and protection of subjects’ personal data consistent 
with applicable privacy  laws .
The informed consent document smust be in compliance wit h ICH GCP, local regulatory  
requirements, and legal requirements , including applicable privacy  laws .
The informed consent document s used during the informed consent process must be 
reviewed and approved by [CONTACT_456], approved by  [CONTACT_1201]/EC before use , and available for 
inspection.
The investigator must ensure that each study  subject is fully  informed about the nature and 
objectives of the stud y and possible risks associated with participation. 
The investigator, or a person designated b y the investigato r, will obtain written informed 
consent from each subject ,before an y study -specific activity  is performed. The investigator 
will retain the original of each subject's signed consent document .
12.4. Subject Recruitment
Advertisements approved by  [CONTACT_1202]/ECs and investigator databases may  be used as 
recruitment procedures.   [COMPANY_007] will have an opportunity  to review and approve the content of 
any study  recruitment materials directed to potential study subjects before such materials are 
used. 
12.5. Reporting of S
afety I ssues and Serious B reaches of the Protocol or ICH GCP
In the event of an y prohibition or restriction imposed (ie, clinical hold) b y an applicable 
competent authorit y in any area of the world, or if the investigator is aware of any  new 
information that might i nfluence the evaluation of the benefits and risks of the investigational 
product, [COMPANY_007] should be informed immediately. 
In addition, the investigator will inform [COMPANY_007] immediately  of any  urgent safet y measures 
taken b y the investigator to protect the study  subjects against any  immediate hazard, and of 
any serious breaches of this protocol or of ICH GCP that the investigator becomes aware of.

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, [ADDRESS_194393] been recruited and completed the study  as 
stated in the regulatory  application (ie, clinical trial application [CTA]) and ethics application 
in the Member State.  Poor rec ruitment (recruiting less than the anticipated number in the 
CTA) by  a Member State is not a reason for premature termination but is considered a 
normal conclusion to the study  in that Member State.
13.2. End of Trial in All Other Participating Countries 
End of trial in all other participating countries is defined as last subject last visit (L SLV). 
14.SPONSOR DISCONTINUAT ION CRITERIA
Premature termination of this study  may  occur because of a regulatory  authority  decision, 
change in opi[INVESTIGATOR_1100]/EC, or investigational product safety  problems, or at the 
discretion of [COMPANY_007].  In addition, [COMPANY_007] retains the right to discontinue development of
tofacitinib for use in subjects with rheumatoid arthritis at any  time.
If a stud y is prematurel y terminated or discontin ued, [COMPANY_007] will promptly  notify  the 
investigator.  After notification, the investigator must contact [CONTACT_8906][INVESTIGATOR_4601]  (if applicable) within 7days.  As directed b y [COMPANY_007], all study  materials 
must be collected and all CRFs completed to the greatest extent possible.
15.PUBLICATION OF STUDY RESULTS
15.1. Communication of Results by [CONTACT_47618].clinicaltrials.gov (Cli nicalTrials.gov), the European Clinical Trials 
Database (EudraCT), and/ or www.pfizer.com, and other public registries in accordance with 
applicable local laws/regulations. 
In all cases, stud y results are reported b y [COMPANY_007] in an objective, accurate, balan ced, and 
complete manner and are reported regardless of the outcome of the stud y or the country in 
which the study  was conducted.
www.clinicaltrials.gov
[COMPANY_007] posts clinical trial US Basic Results on www.clinicaltrials.gov for [COMPANY_007]- sponsored 
interventio nal studies conducted in subjects that evaluate the safet y and/or efficacy of a 
[COMPANY_007] product , regardless of the geographical location in which the study
 is conducted.  US 
Basic Results are submitted for posting within [ADDRESS_194394] for all [COMPANY_007] -sponsored interventional studies that 
are in scope of EU requirements.  EU Basic Results are submitted for posting within 1 year 
of the primary  completion date for studies in adult populations or within 6 months of the 
primary  completion date for studies in pediatric populations.
www.pfizer.com
[COMPANY_007] posts Public Disclosure Sy nopses (clinical study  report sy nopses in which any  data 
that could be used to identify individual subjects has been removed) on www.pfizer.com for 
[COMPANY_007] -sponsored interventional studies at the same time the US Basic Results docum ent is 
posted to www.clinicaltrials.gov.
15.2. Publications by [CONTACT_167192] [INVESTIGATOR_167148], whether or not the results are favorable to the [COMPANY_007] product.  
However, to ensure aga inst inadvertent disclosure of confidential i nformation or unprotected 
inventions, the i nvestigator will provide [COMPANY_007] an opportunity to review any proposed 
publication or other t ype of disclosure of the results of the s tudy (collectively , “Publication”) 
before it is submitted or otherwise disclosed.
The i nvestigator will provide any publication to [COMPANY_007] at least [ADDRESS_194395] to the 
other requirements of this s ection.

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, 04 Dec 2017
Page 83For all publications relat ing to the study, the i nstitution will comply  with recognized ethical 
standards concerning publications and authorship, including Section II -“Ethical 
Considerations in the Conduct and Reporting of Research” of the Uniform Requirements for 
Manuscripts Submitted to Biomedical Journals, http://www.icmje.org/index.html#authorship, 
established by  [CONTACT_4717].
Publication of study  results is also provided for in the CSA between [COMPANY_007] and the 
institution.  I n this sect ion entitled Publications by  [CONTACT_4718], the defined terms shall have 
the meanings given to them in the CSA.
If there is an y conflict between the CSA and an y Attachments to it, the terms of the CSA 
control.  If there is an y conflict between this protoco l and the CSA, this protocol will control 
as to any  issue regarding treatment of 
study subjects, and the CSA will control as to all other 
issues.

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, [ADDRESS_194396] S, Treiber DK, et al. A quantitative anal ysis of kinase inhibitor 
selectivity . Nat Biotechnol 2008; 26:127 -32.
2. Meyer DM, Jesson MI. Anti -inflammatory  activity  and neutrophil reductions mediated 
by [CONTACT_167193]1/JAK3 inhibitor, CP -690,550, in rat adjuvant -induced arthritis. J I nflamm 
(Lond) 2010;7:41.
3. Murray  PJ. The JAK -STAT signaling pa thway : input and output integration. J I mmunol 
2007;178(5):2623 -9.
4. O’Sullivan L A, Liongue C, L ewis RS, et al. C ytokine receptor signaling through the 
JAK STAT -Socs pathway in disease. Mol I mmunol 2007;44(10):2497 -506.
5. Fleischmann R, Cutolo M, Genovese MC, Lee EB, Kanik KS, Sadis S, et al. Phase IIb 
dose-ranging stud y of the oral JAK inhibitor tofacitinib (CP -690,550) or adalimumab 
monotherap y versus placebo in patients with active rheumatoid arthritis with an 
inadequate response to disease- modify ing antirhe umatic drugs. Arthritis and 
rheumatism. 2012;64(3):617 -29. Epub 2011/09/29.
6. Fleischmann R, Kremer J, Cush J, Schulze -Koops H, Connell CA, Bradley  JD, et al. 
Placebo- controlled trial of tofacitinib monotherap y in rheumatoid arthritis. The New 
England journa l of medicine. 2012; 367(6):495- 507. Epub 2012/08/10.
7. Kremer JM, Cohen S, Wilkinson BE, Connell CA, French J L, Gomez -Reino J, et al. A 
phase IIb dose -ranging study  of the oral JAK inhibitor tofacitinib (CP -690,550) versus 
placebo in combination with backgr ound methotrexate in patients with active 
rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis and 
rheumatism. 2012;64(4):970 -81. Epub 2011/10/19.
8. Kremer J, L i ZG, Hall S, Fleischmann R, Genovese M, Martin -Mola E, et al. 
Tofacit inib in combination with nonbiologic disease -modify ing antirheumatic drugs in 
patients with active rheumatoid arthritis: a randomized trial. Annals of internal 
medicine. 2013;159(4):253- 61. Epub 2013/09/13.
9. Burmester GR, Benda B, Gruben D, Bradley  J, Mebus C. Tofacitinib for rheumatoid 
arthritis - Authors' repl y. Lancet. 2013; 381(9880):1812- 3. Epub 2013/05/28.
10. van Vollenhoven RF, Fleischmann R, Cohen S, L ee EB, Garcia Meijide JA, Wagner S, 
et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthr itis. The New 
England journal of medicine. 2012;367(6):508 -19. Epub 2012/08/10.
11. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, et al. American 
College of Rheumatology/European League Against Rheumatism provisional definition 
of remission in rheumatoid arthritis for clinical trials. Arthritis and rheumatism. 
2011;63(3):573 -86. Epub 2011/02/05.

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, 04 Dec 2017
Page 8512. Fries JF, Spi[INVESTIGATOR_110426], Young DY. The dimensions of health outcomes: the health 
assessment questionnaire, disability  and pain scales. The Journal of rheu matology . 
1982;9(5):789 -93. Epub 1982/09/01.
13. Ware JE KM, Dewey  JE.  . How to score Version 2 of the SF 36 Health Survey  
(Standard & Acute forms).  In: How to score Version 2 of the SF 36 Health Survey  
(Standard & Acute forms).  L incoln, Rhode Isla nd: Quali tyMetric, Incorporated. 2000.
14. Hurst NP, Kind P, Ruta D, Hunter M, Stubbings A. Measuring health- related quality  of 
life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ -5D). 
British journal of rheumatology . 1997;36(5):551 -9.Epub 1997/05/01.
15. Reilly  MC, Zbrozek AS, Dukes E: The validity  and reproducibility  of a work 
productivity  and activity  impairment measure.  PharmacoEconomics 1993; 4(5):353 -
365.
16. Cella D, Lai JS, Chang CH, Peterman A, Slavin M. Fatigue in cancer patients co mpared 
with fatigue in the general [LOCATION_002] population. Cancer. 2002;94(2):528 -38. Epub 
2002/03/20.
17. Pi[INVESTIGATOR_35807] T , Yazici Y, Bergman MJ. RAPI D3, an index to assess and monitor patients 
with rheumatoid arthritis, without formal joint counts: similar results to DAS28 and 
CDAI  in clinical trials and clinical care. Rheum Dis Clin North Am. 2009 
Nov;35(4):[ADDRESS_194397] disease -modify ing antirheumatic drug
DMC data monitoring committee
DNA deoxy ribonucleic acid
DU dispensable unit
EC ethics committee
ECG electrocardiogram
EDMC external data monitoring committee 
EDP exposure during pregnancy
EDTA edetic acid (eth ylenediaminetetraacetic acid)
ESR erythrocy te sedimentation rate
EQ-5D European Quality  of Life - 5dimensions questionnaire 
EU European Union
EudraCT European Clinical Trials Database
EuroQol European Quality  of Life 
FACI T Functional Assessment of Chronic Illness Therapy

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, 04 Dec 2017
Page 87FACS fluorescence -activated cell sorting
FDA Food and Drug Administration ([LOCATION_002])
FDAAA Food and Drug Administration Amendments Act (United 
States)
FSH follicle -stimulating hormone
GCP Good Clinical Practice
GGT gamma -glutamyl transferase
GFR glomerular filtrat ion rate
HAQ- DI Health Assessment Questionnaire -Disability  Index 
HBcAb hepatitis B core antibod y 
HbsAb hepatitis B surface antibody  
HbsAg hepatitis B surface antigen 
HDL high density  lipoprotein
HEENT head, ey es, ears, nose and throat
HIV human immunodeficiency  virus
HRQL health- related quality  of life
HZ herpes zoster
IB investigator’s brochure
ICH International Conference on Harmonisation
ID identification
IFNγ Interferon gamma
IL interleukin
IND investigational new drug application
INR international normalized ratio
IRB institutional review board
IRC internal review committee
IUD intrauterine device
IVRS interactive voice response sy stem
JAK janus kinase
IWR interactive web response
LDA low disease activity
LDL low density  lipoprotein
LFT liver function test
LSLV last subject last visit 
LTE long-term extension
MCP metacarpophalangeal
MTX methotrexate
N/A not applicable
NK Natural killer
NSAID nonsteroidal anti -inflammatory  drug
NYHA [LOCATION_001] heart association
PCD prim ary completion date
PhyGA physician’s global assessment of health

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, [ADDRESS_194398] ’s global assessment of health
QD once dail y
RA rheumatoid arthritis
RAPI D3 Routine Assessment of Patient I ndex Data 3
RNA ribonucleic acid
SAE serious adverse event
SAP statistical analy sis plan
SC subcutaneous
SDAI simplified disease activity index
SF-36 short form (36) health survey  
SIB suicidal ideation and behavior
SJC swollen joint count
SOA schedule of acti vities
SOP standard operating procedure
SPC summary  of product characteristics
SRSD single reference safet y document
SSID study  subject identification
TB tuberculosis
TJC tender joint count
TNF tumor necrosis factor
TNFi tumor necrosis factor inhib itor
TST tuberculin skin test
TYK tyrosine kinase
ULN upper limit of normal
US [LOCATION_002]
USPI [INVESTIGATOR_167149]
A3921192
Final Protocol Amendment 2, 04 Dec 2017
Page 89Appendix 2.The 2010 American College of Rheumatology/European League Against Rheumatism Classification Criteria for 
Rheumatoid Arthritis
Score
Target population (Who should be tested?): Patients who
Have at least 1 joint with definite clinical synoviti s (swelling)*
With the synovitis not better explained by [CONTACT_51089]†
Classification criteria for RA (score- based algorithm: add score of categories A -D; a score of ≥6/10 is 
needed for classification of a patient as having definite RA)‡
Joint involvement§
1large joint¶
2-10 large joints
1-3small joints (with or without i nvolvement of large joints) #
4-10 small joints (with or without involvement of large joints)
>10joints (at least 1 small joint)**0
1
2
3
5
Serology (at least [ADDRESS_194399] result is needed for classification) ††
Negative RF and negative ACPA
Low-positive RF or low -positive ACPA
High -positive RF or high- positive ACPA0
2
3
Acute -phase reactants (at least [ADDRESS_194400] result is needed for classification)‡‡
Normal CRP and normal ESR
Abnormal CRP or abnormal ESR0
1
Duration of symptoms §§
<6weeks
≥6weeks0
1
*The criteria are aimed at classification of newly presenting patients.  In addition, patients with erosive disease typi[INVESTIGATOR_2855] o f rheumatoid arthritis 
(RA) w ith a history co mpatible w ith prior fulfillment of the 2010 criteria should be classified as having RA.  Patients with longstanding disease, 
including those whose disease is inactive (with or without treatment) who, based on retrospectively available data, have prev iously fulfilled the 
2010 criteria should be classified as having RA.
†Differential diagnoses vary among patients with different presentations, but may include conditions such as systemic lupus e rythematosus, 
psoriatic arthritis, and gout.  If it is unclear about the relevant differential diagnoses to consider an expert rheumatologist should be consulted.
‡Although patients with a score of <6/10 are not classifiable as having RA, their status can be reassessed and the criteria might be fulfilled 
cumulatively ov er time.

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, 04 Dec 2017
Page 90§Joint involvement refers to any swollen or tender joint on examination, which may be confirmed by [CONTACT_167194].  Distal 
interphalangeal joints, first carpometacarpal joints, and first metatarsophalangeal joints are excluded from assessment.  Categories of joint 
distribution are classified according to the location and number of involved joints, with placement into the highest category possible based on the 
pattern of joint involvement.
¶“Large joints” refers to shoulders, elbows , hips, knees, and ankles.
#“Small joints” refers to the metacarpophalangeal joints, proximal interphalangeal joints, second through fifth metatarsophal angeal joints, thumb 
interphalangeal joints, and wrists.
**In this category, at least [ADDRESS_194401] be a small joint; the other joints can include any combination of large and additional 
small joints, as well as other joints not specifically listed elsewhere (eg, temporomandibular, acromioclavicular, sternoclav icular, etc.).
†† Negative re fers to IU values that are less than or equal to the upper limit of normal (ULN) for the laboratory and assay; low -positive refers to 
IU values that are higher than the ULN but ≤3times the ULN for the laboratory and assay; high -positive refers to IU values that are >[ADDRESS_194402] for the laboratory and assay.  Where rheumatoid factor (RF) information is only available as positive or negative, a posi tive result sho uld be 
scored as low -positive for RF.   ACPA = anti -citrullinated protein antibody.
‡‡Normal/abnormal is determined by [CONTACT_51091].  CRP = C -reactive protein; ESR = erythrocyte sedimentation rate.
§§ Duration of symptoms refers to patient s elf-report of the duration of signs or symptoms of synovitis (eg, pain, swelling, tenderness) of joints 
that are clinically involved at the time of assessment, regardless of treatment status.

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, [ADDRESS_194403] 4 weeks or 
5half-lives ( whichever is longer) prior the Baseline V isit. 
All investigational compounds, other than study  drug s (tofacitinib and MTX), are prohibited 
during the study . 
Please refer to Appendix 6for prohibited c orticosteroids.
Only  systemicall y administered drugs listed below are prohibited; topi[INVESTIGATOR_2855], ophthalmic, or 
intravaginal administration is allowed. 
The use of folate antagonists such as trimethoprim is pr ohibited during the study .
Prohibited Concomitant Medications
CYP3A4 and/or CYP2C19 Inhibitors CYP3A4 Inducers
Protease inhibitors: Protease inhibitors:
indinavir (Crixivan) efavirenz (Sustiva)*
nelfinavir (Viracept) nevirapi[INVESTIGATOR_050] (Viramune)*
ritonavir (Kaletra, Norvir) Anticonvulsants:
Saquinavir (Invirase) barbiturates*
Macrolide antibiotics: phenobarbital*
clarithromycin (Biaxin, Prevpac) phenytoin (Dilantin, Phenytek)
telithromycin (Ketek) carbamazepi[INVESTIGATOR_050] (Carbatrol, Tegretol)*
Other antibiotics: Antibiotics:
chloramphenicol rifampi[INVESTIGATOR_2513]/rifampin (Rifadin, Rifamate)
Antifungals: rifabutin (Mycobutin)*
fluconazole (Diflucan) Rifapentene (Priftin)*
ketoconazole (Nizoral) Antidepressants:
itraconazole (Sporanox)
voriconazole (Vfend)St.  John's Wo rt*
Antidepressants: Other compounds:
fluvoxamine (Luvox) modafinil (Provigil)
nefazodone (Serzone) troglitazone (Rezulin)
Prohibited Concomitant DMARDs**
Biologic DMARDs Nonbiologic DMARDs
Rituximab, anakinra (Kineret), etanercept 
(Enbrel), inflixi mab (Remicade), abatacept 
(Orencia), tocilizumab (Actemra),
certolizumab pegol (Cimzia®),  Golimumab 
(Simponi TM), adalimumab (Humira) , Oral gold (auranofin), injectable gold 
(aurothioglucose, aurothiomalate), sulfasalazine, 
d-penicillamine, bucillamine , mizoribin, 
azathioprine, leflunomide (Arava), 
cyclosporine, tacrolimus , tetracyclines (unless 
prescribed for acne),  antimalarials 
(chloroquine, hydroxychloroquine) , baricitinib
*Discontinue for at least 30 days
** See Section 5.8forspecific w ashout requirements.

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, 04 Dec 2017
Page 92Appendix 4.Cockcroft -Gault Formula for Estimating GFR
Creatinine Clearance (estimated) /Conventional mL/min =
((140 - Age (years) ) XWeight (kg) X Factora) /(72XSerum Creatinine (mg/dL) )
aFactor is equal to 0.8 5 in females and 1.00 in males.

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, 04 Dec 2017
Page 93Appendix 5.Approximate Equivalent Morphine Doses Of Opi[INVESTIGATOR_167150]-Life
Morphine 30mg 1 1.5– 4hrs
Hydrocodone (Vicodin, Lortab) 30mg 1 3.8–4.5hrs
Hydrom orphone (Dilaudid) 7.5mg 4 2.5hrs
Meperidine (Demerol, Pethidine) 300mg 0.1 3.2–3.7hrs
Methadone (Dolophine, 
Methadose, Physeptone)10mg 3.0 23hrs
Codeine (Paveral, Tylenol 
#2and #3)200mg 0.15 2.5–3.5hrs
Oxycodone [Roxicodone; 
Percocet, Tylox]15mg  ~2 3.2hrs
Tramadol [Ultram, Zydol; 
Zamadol, Ultracet, Tramal]300mg ~0.1 4.7–5.1hrs
Sites should contact p roject team for acceptable alternative preparations and related data.
References:
1. Twycross R, Wilcock A, Thorp S. Palliative Care Formulary.   Abingdon: Radcliffe Medical Press, 1998.
2. Twycross R.  Pain relief in advanced cancer. Edinburgh: Churchill Livingstone, 1994.

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, 04 Dec 2017
Page 94Appendix 6.Rescue Therapy
Acetaminophen/ paracetamol is allowable as rescue medication if dosed no more than the 
locally  approved recommended dail y dose for no more than [ADDRESS_194404] 
is alread y taking stable background doses of acetaminophen/ paracetamol, s/he may increase 
the dose up to the locall y approved recommended daily dose for up to 10 consecutive day s 
for rescue purposes.
Acetaminophen/paracetamol is not permitted as a part of combination products such as 
over-the-counter “cold remedies” or in combination with opi[INVESTIGATOR_167151]/paracetamol dose will exceed the locally approved recommended dail y dose.  
Subjects who require rescue for more than 10 consecutive day s should be discontinued from 
the trial.  In a ddition, subjects should not be dosed with rescue acetaminophen/paracetamol 
or opi[INVESTIGATOR_39863] 24 hours prior to a study  visit.  However, baseline stable 
acetaminophen/paracetamol or opi[INVESTIGATOR_167152] y 
visits. 
Low dose o ral corticosteroids in doses equivalent to ≤10mg prednisone per day  is allowed 
during the study  period.   However, the prednisone dose increase should not exceed the initial 
dose during the study  period .
Intra -articular corticosteroids may  be given during the first 3 months of the run -in phase in 
nomore than two joints, in a cumulative dose of no more than 80 mg methy lprednisolone or 
its equivalent during an y 6month study  period.   Injections are not allowed after 3 months.   
Injected joints will also be c onsidered as having their pre
-injection status (tender/painful or 
swollen) for the remainder of the trial.
Intravenous or intramuscular corticosteroids are not allowed during this study . 
Biologic response modifiers are not allowed during this study .
Subj ects should not be dosed with any rescue intervention within 24 hours prior to a 
study visit.
The following paradigm should be used to determine appropriate opi[INVESTIGATOR_167153]:
For subjects who are NOT on stable, background opi[INVESTIGATOR_2538]: any of the fo llowing 
single opi[INVESTIGATOR_167154] (with or without acetaminophen/ 
paracetamol) for no more than 10 consecutive days in the following total daily  doses:
1.Hydrocodone, not to exceed 30 mg total daily  dose.
2.Oxycodone, not to exceed 15mg total daily  dose.
3. Tramadol, not to exceed 300 mg total daily  dose.

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, 04 Dec 2017
Page 95For subjects who ARE on stable, background opi[INVESTIGATOR_2538] :
1.They  may  NOT add a second opi[INVESTIGATOR_167155].
2. If their background medication is 1 of the 3 listed above, they  may , within the above 
maximum total dosage limits, increase the dosage for up to 10 consecutive day s for 
rescue purposes.
3.If their background medication is a short -acting (half -life <5 hours, Appendix 5) 
opi[INVESTIGATOR_167156], they  may  increase the dosage for up to 
10consecutive day s (up to a total daily  dose which must not exceed the potency  
equivalent of 30 mg o f orally -administered morphine ( Appendix 5) for rescue 
purposes.
4.Sustain ed release opi[INVESTIGATOR_167157] (eg, Ox yContin®, MS Contin®) and opi[INVESTIGATOR_167158]
-lives greater than 5 hours (eg, methadone) may  NOT be USED for rescue 
medication.
5.Sustained release opi[INVESTIGATOR_167157] (eg, Ox yContin®, MS Contin®) and opi[INVESTIGATOR_167158]- lives greater than 5 hours (eg, methadone; see also Appendix 4) may  NOT 
be INCREASED for rescue purposes.

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, 04 Dec 2017
Page 96Appendix 7. Belgium, Czech Republic, [LOCATION_013], Hungary, Italy, Poland, Spain, and 
[LOCATION_008] Specific Protocol Requirements
In Belgi um, Czech Republic, [LOCATION_013] , Hungary , Italy, Poland, Spain, and the United 
Kingdom , the following changes are made to the protocol :
4.4.5 Contraception and Reproductive Status
In this stud y, male subjects who are able to father children and female subjects who are of 
childbearing potential will receive MTX, which has been associated with teratogenic risk in 
humans, and tofacitinib which has been associated w ith teratogenic risk in animals (further 
information can be found in the single safet y reference document) .  Those who, in the 
opi[INVESTIGATOR_871], are sexuall
y active and at risk for pregnancy with their partner(s) 
must agr ee to use with their partner(s) highl y effective contraception throughout the study 
and continue for at least [ADDRESS_194405] and his/her partner(s) from the list of permitted contraception methods 
below and inst ruct the subject in their consistent and correct use.  The investigator or his or 
her designee will discuss with the subject the need to use a highly  effective method of 
contraception consistently and correctl y according to the schedule of activities and document 
such conversation, and the subject’s affirmation, in the subject’s chart.  In addition, the 
investigator or his or her designee will instruct the subject to call immediately  if a selected 
contraception method is discontinued or if pregnancy  is known or suspected in the subject or 
the subject’s partner. 
Highly  effective methods of contraception are those that, alone or in combination, result in a 
failure rate of less than 1% per year when used consistently  and correctly  (ie, perfect use) .
One of the below options must be used to satisfy  the requirement for highly  effective 
contraception :
1.Established use of hormonal methods of contraception associated with inhibition of 
ovulation (ie, oral, inserted, injected, implanted, tran sdermal) with either :
a.male condom or female condom used WI TH a spermicide (ie, foam, gel, film, 
cream, or suppository ).  For countries where spermicide is not available, this 
option is not appropriate;
b.male sterilization.
2.Correctly placed copper -containing intrauterine device (IUD) or intrauterine sy stem 
combined with either :
a.male condom or female condom used WI TH a spermicide (ie, foam, gel, film, 
cream, or suppository ).  For countries where spermicide is not available, this 
option is not appropriate;

Tofacitinib citrate
A3921192
Final Protocol Amendment 2, 04 Dec 2017
Page 97b.male sterilization . 
3.Male sterilization with absence of sperm in the postvasectomy  ejaculate combined 
with:
a.male condom or female condom used WI TH a spermicide (ie, foam, gel, film, 
cream, or suppository .  For countries where spermicide is not available, this 
option is not appropriate;
b. bilateral tubal ligation/bilateral salpi[INVESTIGATOR_167159] . 
4.Bilateral tubal ligation / bilateral salpi[INVESTIGATOR_8820] y or bilateral tubal occlusive procedure 
(provided that occlusion has been confirmed in ac cordance with the device’s label)
combined with:
a.IUD or intrauterine s ystem;
b.male condom or female condom used WI TH a spermicide (ie, foam, gel, film, 
cream, or suppository ).  For countries where spermicide is not available, this 
option is not appropriate;
c.male sterilization.
Pregnancy  testing will be performed and documented at every  visit unless the 
non-childbearing potential is confirmed and documented.  The specific contraceptive 
methods will be documented and at every
 visit, their consistent and correc t use will be 
ascertained and documented in the subject’s case report form.
